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ABSTRACT 
The most deadly aspect of cancer is its ability to spread from its original 
location to other sites in the body and grow as distant metastases. Formation 
of metastases is a multistep process and metastases can form even decades 
after the removal of the primary tumor. Cell surface proteins are known to 
play central roles in the adhesive contacts and molecular interactions 
between the tumor cell and the stroma during various stages of metastasis. In 
addition, they mediate important signals to intracellular proteins. As the 
detailed mechanisms of metastasis are still unclear, the aim of this thesis was 
to discover novel metastasis-associated cell surface proteins for further 
investigation. 
This thesis established an optimized method for the isolation of 
biotinylated cell surface proteins for proteomic identification. This method 
was applied to compare the cell surface proteins isolated from an isogenic 
pair of human MDA-MB-435 cancer cell line with opposite metastatic 
phenotypes. We found 29 differentially expressed proteins and analyzed the 
molecular pathways they were involved in. Of these proteins expression of 
CD109 was shown to mark metastatic melanoma cells and invasive breast 
cancer cells. 
 Nucleophosmin (NPM) is a multitasking protein with both oncogenic and 
tumor suppressive functions. In our comparative proteomics analysis we 
discovered NPM to be expressed on the surface of the non-metastatic 
subclone of the MDA-MB-435 cells. We showed that NPM was detected at 
different localizations in the non-metastatic and metastatic cells most likely 
due to the expression of novel NPM splice variants discovered in this thesis 
work. In addition, we showed that expression level of NPM is one mechanism 
affecting its localization. In regards to patient prognosis, we revealed that 
high levels of NPM were expressed in the luminal epithelial cells of 
histologically normal breast tissue and that high levels independently 
associated with good prognosis in the luminal A breast cancer subtype. On 
the contrary, novel granular staining pattern and Threonine199 
phosphorylation of NPM (NPMpThr199) correlated with aggressive 
characteristics, basal subtype and poor prognosis of human breast cancer. 
Moreover, NPMpThr199 associated with expression of a recently identified 
oncogene, cancerous inhibitor of protein phosphatase 2 (CIPA2). 
In brief, this study provides several novel metastasis associated cell 
surface proteins for future investigation.  By using breast cancer tumor 
microarrays from two large breast cancer patient cohorts and cellular models 
this thesis demonstrates for the first time, that different NPM forms play 
divergent and opposite roles in breast cancer. 
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TIIVISTELMÄ 
Syöpä on sairaus, jossa kehon solut jakaantuvat kontrolloimattomasti ja 
leviävät alkuperäisestä kasvupaikastaan elimistön muihin kudoksiin 
muodostaen niihin etäpesäkkeitä. Tämä johtaa potilaan kuolemaan. Syövän 
leviäminen ja etäpesäkkeiden muodostuminen on monivaiheinen prosessi, 
jonka kaikkia yksityiskohtia ei vielä tarkkaan tunneta. Koska syöpäsolut 
hyödyntävät solujen pinnalla ilmentyneitä proteiineja kommunikoidessaan 
ympäristönsä kanssa, näillä proteiineilla on tärkeä rooli syövän leviämisessä 
uusin kasvupaikkoihin. Väitöskirjatyöni tarkoituksena oli tunnistaa 
etäpesäkkeiden muodostumisen kannalta tärkeitä solun pintaproteiineja, 
joita ei ole aikaisemmin yhdistetty syövän leviämiseen. 
Tutkimuksessa löysimme 29 proteiinia, joiden ilmentymisellä 
syöpäsolujen pinnalla oli yhteys solujen kykyyn muodostaa etäpesäkkeitä.   
Yksi löytämistämme proteiineista oli CD109, jota löytyi sekä etäpesäkkeistä 
eristetyistä melanoomasoluista että rintasyöpäsoluista, jotka pystyivät 
leviämään ympäröivään kudokseen. Jatkotutkimuksissa tulisi selvittää, 
voisiko CD109:n ilmentymistä käyttää syövän ennusteellisena tekijänä. 
Lisäksi tulisi selvittää, miten CD109:n läsnäolo syöpäsolujen pinnalla auttaa 
niitä leviämään elimistössä.  
Tutkimuksen toisessa osassa löysimme merkittävän yhteyden 
nukleofosmiini-proteiinin (NPM) ilmentymistason ja potilaiden ennusteen 
välillä laajassa rintasyöpäaineistossa. Potilailla, joiden syöpäkasvaimissa 
NPM:n määrä oli vähentynyt, oli suurentunut riski etäpesäkkeiden 
muodostumiseen ja rintasyövästä aiheutuvaan kuolemaan.  Lisäksi 
osoitimme solukokeissa NPM:n vähentävän rintasyöpäsolujen 
aggressiivisuutta.  Nämä tuloksemme tukevat NPM:n tuumorisuppressiivista 
(kasvua estävää) toimintaa rintasyövässä. Toisaalta havaitsimme, että 
potilaiden huonoon ennusteeseen ja etäpesäkkeiden muodostumiseen 
vaikuttaa NPM:n treoniini-199-fosforylaatio. Havainto on merkittävä, sillä 
NPM:n toiminta on usein häiriintynyt kasvaimissa, mutta tämän häiriön 
taustalla vaikuttavia mekanismeja ei tarkkaan tunneta. Tutkimustuloksemme 
osoittavat sekä NPM:n ilmentymismäärän että sen fosforylaation vaikuttavan 
tämän proteiinin toimintaan rintasyövässä. 
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ABBREVIATIONS 
AML acute myelod leukemia 
ARF p14ARF 
ATP Adenosine-5'-triphosphate 
BLBC basal like breast cancer 
CIP2A cancerous inhibitor of protein phosphatase 2 
CD109 cluster of differentiation 109 
CDK cyclin-dependent kinase 
CK2 casein kinase 2 
CK5/6 cytokeratin-5/6 
CSCs cancer stem cells 
CTCs  circulating tumor cells 
DTCs disseminated tumor cells  
ECM extracellular matrix 
ECGFP enhanced cyan green fluorescent protein  
EGFR epidermal growth factor receptor 
EMT epithelial to mesenchymal transition 
ER estrogen receptor  
GRK5 G protein-coupled receptor kinase 5 
HER1 human epidermal growth factor receptor-1   
HER2 human epidermal growth factor receptor-2 
IGSF8 immunoglobulin superfamily member 8 
ITGA6 integrin-α6  
ITGB1 Integrin-β1 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LC-MS/MS liquid chromatography coupled to tandem mass spectrometry 
MDM2 murine double minute 2 
MEFs mouse embryonic fibroblasts 
NPM nucleophosmin  
pThr199 threonine 199 phosphorylation 
PP1 protein phosphatase 1 
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PR progesterone receptor 
PROCR endothelian protein C receptor 
PTGFRN prostaglandin receptor negative regulator 
PTP protein tyrosine phosphatase 
PTPRF receptor-type tyrosine-protein phosphatase F 
RB retinoblastoma protein 
rRNA ribosomal RNA 
SENP SUMO1/sentrin/SMT3 specific peptidase  
SSR4 Translocon associated protein delta subunit 
SUMO Small ubiquitin-like modifier  
TICs tumor initiating cells 
TMA tissue microarray  
TME tumor microenvironment 
TNBC triple negative breast cancer 
VAMPA membrane protein-associated protein A 
2D two dimensional 
3D  three dimensional 
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1 INTRODUCTION 
Cancer comprises a large group of diseases caused by deregulated cell growth 
and resistance to cell death in any part of the body. Every fourth person in 
Finland is diagnosed with cancer at some point of their life (Cancer Statistics 
at Finnish Cancer Registry) and according to the World Health Organizations 
GLOBOCAN 2008 project 7.6 million annual cancer deaths are reported 
worldwide (Ferlay et al., 2011). The most deadly aspect of cancer is its ability 
to spread from its original location to other sites in the body in a process 
referred to as metastasis. Metastasis is a multistep process, details of which 
are not yet fully understood. Therefore, there is a need to identify novel 
proteins and molecular pathways that are involved in the regulation of cancer 
metastasis to better understand and disrupt the process. 
Proteins perform many important cellular functions. Mutations  in 
protein encoding genes can modify protein function in many diseases such as 
cancer (Futreal, 2004). To understand how cancer cell acquires a metastatic 
phenotype, it is important to know the quantities of different proteins in 
normal and malignant cells and understand how these quantities change. 
Proteomics techniques are used to study proteins present in a cell, tissue or 
an organism at given time and can be applied to find changes in proteins and 
their quantities between different conditions or cell types like metastatic and 
non-metastatic tumor cells. 
Tissue microarrays (TMAs) allow analysis of tissue specimens at nucleic 
acid or protein level (Kononen et al., 1998; Avninder et al., 2008). These 
have vastly facilitated the clinical validation of molecular discoveries made 
with the aid of genomics and proteomics methods. TMAs are constructed 
from archival formalin-fixed paraffin embedded tissue and can contain 
patient follow-up data to help classify the clinical significance of the findings. 
In this thesis work, proteomics was used to find novel proteins that might 
play important roles in cancer metastasis. Furthermore, the role of one of the 
identified proteins, nucleophosmin (NPM), was analyzed in breast cancer by 
using TMAs as well as cell biological and biochemical methods. 
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2 REVIEW OF THE LITERATURE 
2.1 Heterogeneity of cancer  
Cancer refers to a collection of heterogeneous malignancies in various 
locations in the body. Cancer is caused by uncontrolled cell growth and 
resistance to cell death. Slow accumulation of alterations in proto-oncogenes, 
tumor-suppressor genes, DNA-repair genes and microRNA genes together 
with epigenetic changes in one cell or a small group of cells is considered to 
lead to cancer development with varying times depending on the tumor type. 
Recent, debatable theories suggest that not all cancer cells in a tumor are 
alike and that only so called cancer stem cells (CSCs) or tumor-initiating cells 
(TICs) would be able to maintain the tumor by possessing the ability to self-
renew and proliferate. Other tumor cells would differentiate into cells that 
constitute the bulk of the tumor mass (Reya, 2001; Zhou, 2009). The 
neoplastic cancer cells harboring genetic alterations do not manifest the 
disease alone but form organ-like structures together with the tumor 
microenvironment (TME), which is composed of different types of normal 
stromal cells and the extracellular matrix (ECM). Consequently, cancer 
formation depends on both cancer cell-intrinsic pathways and cancer cell-
extrinsic pathways (Hanahan, 2012). 
Cancers are categorized into different types depending on their tissue of 
origin. Carcinomas like lung, breast and colon cancer originate from 
epithelial tissues and represent the most common cancer type. Non-epithelial 
cancers can be divided into i) sarcomas which originate from mesenchymal 
cells, ii) hematological cancers (leukemias and lymphomas), which originate 
from hematopoietic cells and iii) neuronal cancers (gliomas, glioblastomas, 
neuroblastomas, schwannomas, medulloblastomas) which originate from 
various components of the central and peripheral nervous system. Recent 
gene array technologies have, however, revealed a heterogeneity in tumors 
appearing in the same organ i.e. lung (West et al., 2012), skin (Vidwans et al., 
2011) or breast (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Hu 
et al., 2006) . This information can be used to separate the breast, skin or 
REVIEW OF THE LITERATURE 
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lung tumors into several distinct molecular subtypes and in the future help to 
develop individual treatment guidelines for the different subtypes. 
2.1.1 Intrinsic breast cancer molecular subtypes 
 
Breast cancer is a heterologous group of diseases in terms of histology, 
therapeutic response, metastatic dissemination, and patient outcomes and it 
has recently been divided into the following intrinsic biological subtypes 
(Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Hu et al., 2006): 
Luminal A, Luminal B, basal-like breast cancer (BLBC), human epidermal 
growth factor receptor-2-enriched (HER2-enriched) and normal-like. Of 
these, Luminal A and B are positive for estrogen receptor (ER) while BLBC 
and HER2-enriched tumors are ER negative (Goldhirsch et al., 2011). 
Luminal A and B subtypes differ from each other in their HER2 expression 
and/or proliferation index so that luminal A tumors are HER2-negative and 
luminal B tumors HER2-positive. Recently, a new instrinsic, claudin low 
subtype of breast cancer, was also suggested (Prat et al., 2010). 
Gene expression profiling is not used in clinical practice to classify 
tumors. Therefore, the gene array-based intrinsic subtypes have been 
evaluated in immunohistochemistry by using antibodies against common 
markers determining the subtypes: ER, progesterone receptor (PR) and 
HER2. In addition, epidermal growth factor receptor (EGFR) (Carey et al., 
2006), cytokeratin-5/6 (CK5/6) (Carey et al., 2006; Nielsen et al., 2004; 
Blows et al., 2010), and markers like human epidermal growth factor 
receptor-1  (HER1) (Nielsen et al., 2004) or  Ki67 (Hugh et al., 2009; Cheang 
et al., 2009)  have been used to classify the basal subtype, depending on the 
study. 
The molecular subtypes differ in their mutation status for the tumor 
suppressor protein p53. Only about 12-15% of luminal A tumors harbor p53 
mutations while function of p53 is lost by mutation or other means in most of 
the BLBCs (Carey et al., 2006; Cancer Genome Atlas Network, 2012; Dumay 
et al., 2013). In addition to molecular subtypes, breast cancers can be 
classified as triple negative (TNBC), which shows negative staining for HER2, 
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ER and PR (Reis-Filho and Tutt, 2008). TNBCs comprise of various kinds of 
tumors, but majority of them are BLBCs (Carey et al., 2010). The tumor 
suppressor RB is commonly affected in TNBC and BLBC (Gauthier et al., 
2007; Herschkowitz et al., 2008; Subhawong et al., 2009). In addition, most 
BRCA1 mutant breast cancers are both triple negative and basal-like (Turner 
and Reis-Filho, 2006; Atchley et al., 2008; Hartman et al., 2012). 
The prognosis of breast cancer patients is generally favorable and 
mortality has declined due to early detection and improved adjuvant 
therapies (Schopper and de Wolf, 2009). However, the metastatic 
dissemination of breast cancer to other organs is not uncommon and women 
with advanced disease still have a median survival time of only 
approximately two years (Largillier et al., 2008; Anderson et al., 2000). 
Currently, most of the breast cancer patients are treated with adjuvant 
therapy because of the lack of proper prognostic and predictive markers of 
metastasis. Novel markers of metastasis are needed to help clinicians to 
select the estimated 40% of patients that will benefit from the adjuvant 
therapy. In addition, the quality of life would increase for the patients that 
can be cured by local treatment only since they would not have to needlessly 
suffer from the side effects of the adjuvant therapy (Weigelt et al., 2005). 
The molecular differences in breast cancer subtypes result in distinct clinical 
outcomes and responses to treatment; in general, the luminal A tumors 
associate with favorable and the BLBC and HER2-enriched tumors with poor 
prognosis (Carey et al., 2006; Voduc et al., 2010; Dawood et al., 2011; Arvold 
et al., 2011; Sorlie et al., 2001). The subtypes also have distinct preference for 
their metastatic sites. Luminal A cancers metastasize first to bone, HER2-
enriched cancers to liver and lung and basal cancers to liver and brain (Sihto 
et al., 2011; Smid et al., 2008). 
The biological mechanisms for breast cancer heterogeneity are mainly 
unknown. Possible explanations include distinct cell of origin, like CSCs or 
progenitor cells and tumor subtype–specific genetic events. These two 
mechanisms are not necessarily mutually exclusive. Two major epithelial cell 
populations are found in the mammary gland; the inner luminal epithelial 
cells and the outer (basal) myoepithelial cells, embedded in a stromal matrix. 
REVIEW OF THE LITERATURE 
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These two populations can be divided in further sub-populations. For 
example, the luminal layer is a mixed population of ER positive and ER 
negative cells. Functionally, the mammary epithelial cells can be classified as 
stem, progenitor and differentiated cells. Luminal compartment contains 
majority of the progenitor cells while the stem cell activity is mainly found in 
the basal layer (Molyneux and Smalley, 2011).  Mouse models (Ginestier et 
al., 2012) and the presence of these different cell populations in the 
mammary gland supports the hypothesis that breast cancer heterogeneity 
would result from different molecular changes occurring in different cell 
types (Dontu et al., 2003). Recent research indicates that BRCA1-associated 
breast cancers and potentially also non-familial BLBC and TNBC would 
originate from the luminal ER negative progenitors (Molyneux and Smalley, 
2011). 
2.2 Metastatic dissemination of cancer  
 
One of the hallmarks in cancer progression is the acquisition of an invasive 
phenotype that allows cancer cells to spread to distant sites in the body and 
form metastatic lesions that are resistant to many cancer treatments 
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). The term 
“metastasis” was invented in 1829 by a French gynecologist Recamier 
(Recamier, 1829) to describe the spread of cancer from its original growth 
sites to other parts in the body. Even today, the metastatic dissemination, 
rather than the primary tumor, is responsible for 90% of cancer deaths 
making metastasis the most serious challenge for cancer treatment (Gupta 
and Massague, 2006).The formation of metastasis depends on multiple steps 
the details of which are still poorly understood. In addition to the tumor cells 
TME or stroma participates in tumor progression, metastasis and response 
to treatment (Sleeman et al., 2012; Joyce and Pollard, 2009). In breast 
cancer, ECM and numerous stromal cell types, including endothelial and 
immune cells, fibroblasts, and adipocytes make up the primary tumor TME 
(Place et al., 2011).  
 15 
Proteins and multiprotein complexes at the cell surface play important 
roles in sensing the environment, the signaling and the adhesive contacts 
between tumor and stromal cells during different stages of the metastatic 
dissemination (Karhemo et al., 2012; Place et al., 2011; Bendas and Borsig, 
2012). In addition, tumor cells use their cell surface proteins to interact with 
platelets, leukocytes, and soluble components during the establishment of 
metastatic lesions (Bendas and Borsig, 2012). In the following paragraphs 
some examples of known cell surface proteins affecting the different parts of 
the metastasis process are given. 
2.2.1 The metastatic cascade  
 
Cancer cells must complete a set of well-defined, interrelated steps, globally 
referred to as the metastatic cascade, to develop clinically detectable 
metastases. Cancer cells must detach from the primary tumor, invade and 
survive in the lymphatics and/or blood vessels to be transported to distant 
organs where they must adhere, extravasate, and proliferate to form a 
metastatic lesion (Valastyan and Weinberg, 2011; Fidler, 2003) (Figure 1). 
Due to the complexity of the metastasis cascade, metastasis is an 
inefficient process and can fail at any step (Chambers et al., 2002; Mehlen 
and Puisieux, 2006; Fidler, 1970). The entry of tumor cells into the 
circulation is common and more than a million cells per gram of tumor can 
be shed daily (Butler and Gullino, 1975). However, only a fraction of the shed 
tumor cells actually survive in the circulation as circulating tumor cells 
(CTCs) or in bone marrow as disseminated tumor cells (DTCs) (Ross and 
Slodkowska, 2009; Mehlen and Puisieux, 2006). 
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Figure 1. The Invasion-Metastasis Cascade. To be able to grow as a distant metastasis, 
cancer cell need to go through a series of different steps termed the invasion-metastasis 
cascade. The cell needs to invade the surrounding tissue (local invasion), enter the 
circulation (intravasation), survive in the circulation to be transported to distant sites. A 
cancer cell needs to be able to attach to the capillary wall at the distant organ, 
extravasate to form micrometastasis. Finally, to grow as a full-blown metastasis, cancer 
cell needs to avoid metastatic dormancy and proliferate at the distant site. (Adapted and 
modified from (Valastyan and Weinberg, 2011)). 
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Recently, it was suggested that this complex metastatic cascade could be 
simplified into two major phases: i) physical translocation from the primary 
tumor to the distant organ (contains the invasion, survival in the circulation 
and transport to the distant site) and ii) colonization at the distant site 
(Chaffer and Weinberg, 2011). The molecular mechanisms underlying the 
first phase are quite well resolved.  During embryogenesis cells lose their 
epithelial characteristics and gain mesenchymal properties in a process 
entitled epithelial to mesenchymal transition (EMT). EMT is considered to 
play a role at least in the first phase of metastasis by changing the adhesive 
properties of tumor cells and promoting their motility, thereby increasing 
their invasiveness (Berx et al., 2007). However, the functional contribution of 
EMT to metastasis in patients is still debated (Sleeman et al., 2012).  
At the cell surface perspective, deregulated expression of many cell 
surface ECM remodeling enzymes like heparanases and matrix 
metalloproteinases is a common event in human cancers to help cancer cells 
in their invasion (Lu et al., 2011). In most tumors cell surface proteins and 
protein complexes like integrins, syndecans, dystroglycans, immunoglobulin 
superfamily cell adhesion proteins, cadherins, and hyaluronan binding 
proteins (hyaladherins) like CD44 participate in cell–tissue interaction and 
migration during invasion (Gritsenko et al., 2012). Recently, microvesicles, 
small membrane-enclosed sacs, shed from tumor cells have been shown to 
participate in the regulation of the ECM invasion and evasion of the immune 
response (Muralidharan-Chari et al., 2010).   
The mechanisms playing a role in the second phase of metastasis, 
colonization still remains largely unknown. In experimental models survival 
and proliferation at the secondary site, have been shown to be highly 
inefficient (Allan et al., 2006). Clinically, it would be of utmost importance to 
better understand the second phase to be able to treat patients who have 
already developed metastasis at the time of diagnosis (Chaffer and Weinberg, 
2011). Most likely, cell surface proteins play a major role also in this phase. 
The models mentioned above describe metastasis as a unidirectional 
process, where cancer cells from the primary tumor seed metastasis in 
distant sites. Interestingly, based on recent experimental models a new 
REVIEW OF THE LITERATURE 
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metastasis concept, termed self-seeding, has been proposed.  This paradigm 
considers metastasis as a multidirectional process whereby cancer cells can 
seed distant sites as well as the primary tumor itself (Norton and Massague, 
2006; Comen et al., 2011). 
2.2.2 Organ specific colonization and microenvironment 
 
The distribution of full-blown metastases to different organs is not random 
and different tumor types disseminate and form metastatic lesions in a 
different set of organs (Auerbach et al., 1987; Johnson et al., 1991; Nguyen et 
al., 2009). Already in 1889 Stephen Paget proposed, based on his analysis of 
autopsy records from 735 breast cancer patients, that DTCs, or “seeds,” 
would only colonize organ microenvironments, or “soils,” that wwould be 
compatible with the growth of the DTCs (Paget, 1889). This so called seed 
and soil hypothesis suggested that outcome of metastasis depends on the 
interactions between the tumor cells and host tissue, a fact that is currently 
emerging as a critical determinant of metastasis (Lorusso and Ruegg, 2012). 
The seed and soil hypothesis was challenged by Ewing by stating that 
organ specificity is accounted by mechanical forces and circulatory patterns 
between the primary tumor and the secondary site (Ewing, 1928). Later, 
Fidler and coworkers (Fidler and Kripke, 1977; Hart and Fidler, 1980) 
revealed that although CTCs in the vasculature traffic through all organs, 
metastases selectively develop in organs with suitable environment. In 
support of this, breast cancer frequently metastasizes to the lungs, bones and 
liver (Largillier et al., 2008) and brain (Palmieri et al., 2006), which do not 
have a direct circulatory connection to breast tissue (Lorusso and Ruegg, 
2012).  
Mechanistically, networking of cytokines and chemokines expressed in 
the target tissue and interacting with their cognate receptors expressed on 
the surface of the tumor cells is involved in organ specificity highlighting the 
important role of cell surface proteins in this process. As examples, 
production of osteoclast-activating factors such as pTHRp, Il-11, Il-6, tumor 
necrosis factor-α (TNFα), and granulocyte–macrophage colony stimulating 
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factor (GM-CSF) is required for the ability of breast cancer cells to form bone 
metastases (Nguyen et al., 2009).  
Recent evidence from cell line and animal studies suggests that specific 
cell surface adhesion molecules on tumor cells and their receptors on the 
lung endothelium mediate breast cancer cell adhesion and extravasation in 
the lung (Lu and Kang, 2007). In breast cancer, the CXCR4 and CCR7 
receptors, expressed on breast cancer cell surface and their ligands CXCL12 
and CCL21 on the organs, might play a role in cancer cell arrest and 
migration into secondary organs (Muller et al., 2001; Wang et al., 2006). 
Metadherin, which is overexpressed on the surface of metastatic breast 
cancer cells, mediates targeting of tumor cells specifically to the lung, but not 
to other organs through binding to an unknown receptor expressed in lung 
endothelium (Brown and Ruoslahti, 2004). In addition, interaction of cell 
surface fibronectin with a dipeptidyl peptidase IV (DPP IV, (Cheng et al., 
1998) and cell surface expression of α6β4 integrin and its  adhesion to 
human CLCA2 protein (Abdel-Ghany et al., 2001) were shown to participate 
in the lung metastasis of breast cancer.  
As described, the successful engraftment and growth of cancer cells in 
distant organs depends on a receptive microenvironment. Recent evidence 
points out that growth factors and other molecules secreted by the primary 
tumor could prime certain tissues for tumor cell engraftment by forming a 
pre-metastatic niche (Psaila and Lyden, 2009; Psaila et al., 2006). The 
location of these pre-metastatic niches would subsequently determine the 
organs in which metastases will form (Sleeman and Cremers, 2007). 
2.2.3 Dormancy of tumor cells 
 
Metastases can occur after long latency periods that range from years to 
decades after the primary treatment (Chaffer and Weinberg, 2011). For 
example, about 45% of breast cancer patients will relapse and develop distant 
metastases years or decades after the diagnosis (Karrison et al., 1999). This 
prolonged time observed for the development of distant, metastatic disease 
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indicates a period of dormancy before DTCs are able to grow into clinically 
relevant metastases (Castano et al., 2011).  
In an experimental model, dormant tumor cells have been observed in 
metastasis free organs of animals carrying spontaneously metastatic primary 
tumors (Suzuki et al., 2006) suggesting that dormancy might also affect 
organ specific colonization so that in the hostile environments DTCs undergo 
dormancy while in a receptive environment the same cells are able to grow 
into macrometastases.  
Concept of tumor cell dormancy was introduced already in 1934 by an 
Australian pathologist Rupert Willis (Willis, 1934). Despite the early 
observation of cancer dormancy, not much is known about cancer cells 
during this period of dormancy and what awakens them even thought this is 
clinically a very important question (Uhr and Pantel, 2011). Dormant cells 
may be reactivated by modification of their microenvironment (Barkan et al., 
2010; Barkan et al., 2010) or by loss of metastasis suppressor genes, which 
are defined by their ability to inhibit overt metastasis in a secondary organ 
without affecting tumor growth at the primary site (Horak et al., 2008).  
Two forms of dormancy, which are not mutually exclusive, have been 
suggested (Castano et al., 2011). Dormancy might be accounted for by a 
mitotic arrest of tumor cells (Naumov et al., 2002; Goodison et al., 2003; 
Muller et al., 2005), which is called cellular dormancy (Castano et al., 2011).  
In another form of dormancy, called tumor dormancy, the rate of cell death 
counterbalances the rate of cell proliferation within a tumor mass (Meng et 
al., 2004; Naumov et al., 2006). However, the mechanisms controlling the 
size of the tumor cell population are unknown (Meng et al., 2004) but it 
might be kept constant by some of the same mechanisms that control the size 
of normal organs (Uhr and Pantel, 2011). 
The molecular mechanisms of dormancy have mostly been studied in 
experimental models. Dormant state might be regulated by a crosstalk 
between tumor cell surface proteins and the ECM at the secondary sites 
(Barkan et al., 2010). As examples, cell surface urokinase receptor (Aguirre 
Ghiso et al., 1999; Liu et al., 2002; Heiss et al., 1995; Aguirre-Ghiso et al., 
2001) and integrin β1-focal adhesion kinase (FAK) signaling axis has been 
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shown to regulate metastatic dormancy in three dimensional in vitro model 
(Shibue and Weinberg, 2009; Pontier and Muller, 2008). Maintenance of the 
dormant state might also be affected by failure of angiogenesis (Goss and 
Chambers, 2010). Recently, Kim et al. revealed a dormancy signature in 
breast cancer and showed that ER-positive tumors, which generally associate 
with favorable prognosis and carry a dormancy signature, are likely to 
undergo prolonged dormancy before resuming metastatic growth (Kim et al., 
2012). 
2.2.4 When tumor cells acquire their metastatic capability? 
 
To understand the properties of metastatic tumor cells and target the 
process, it is important to resolve, when the tumor cells acquire their full 
metastatic capability and are able to go through both phases of metastasis. 
Two basic models have been suggested to represent the timing of the 
metastatic cascade during tumor progression. The prevailing, so called linear 
progression model, suggests that a rare subpopulation of tumor cells in the 
primary tumor acquires a full malignant phenotype via genomic alterations 
at late stages of primary tumor development. These fully malignant cells 
would have all the properties required for the formation of metastatic lesions 
(Fidler and Kripke, 1977; Klein, 2009; Poste and Fidler, 1980). The 
association of large tumor size with higher frequency of metastases 
(Koscielny et al., 1984), the correlation between primary tumor size and risk 
of lymph node and distant metastasis (Comen et al., 2011), the curative effect 
of surgery on smaller lesions (Klein, 2009) and the variable metastatic 
capability of different murine B16 melanoma cell clones (Fidler and Kripke, 
1977) support the linear progression model.  
A recent, parallel model of metastasis questions the linear progression 
model and proposes that metastases arise from DTCs, which do not 
necessarily disseminate near the end of primary tumor development and 
acquire their fully metastatic phenotype independent of the primary tumor 
(Klein, 2009).  Quantitation of human cancer growth rates demonstrates that 
the metastatic lesions must have been initiated long before the diagnosis of 
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the primary tumor (Collins et al., 1956; Friberg and Mattson, 1997; Klein, 
2009). Furthermore, the long interval between diagnosis and relapse with 
metastatic, distant disease in breast cancer, e.g. dormancy, supports the 
parallel progression model (Nguyen et al., 2009). In addition, genetic 
comparison of breast cancer metastases to their matched primary tumors 
supports the parallel progression and early onset of metastases (Sleeman et 
al., 2012; Kuukasjarvi et al., 1997; Torres et al., 2007; Santos et al., 2008). In 
addition, recent studies show that breast cancer derived DTCs display fewer 
genetic alterations than their corresponding primary tumors  (Schardt et al., 
2005; Schmidt-Kittler et al., 2003) and these alterations do not resemble 
those detected in the corresponding primary tumors (Lorusso and Ruegg, 
2012; Schmidt-Kittler et al., 2003; Braun et al., 2005). However, DTCs are 
currently isolated for analysis by the aid of certain epithelial markers, which 
might not be expressed by all DTCs such as tumor cells undergoing EMT 
hampering the reliable comparison of all DTCs to primary tumors (Sleeman 
et al., 2012).  
It has also been suggested that particular early oncogenic events that 
drive primary tumor growth might give cancer cells their propensity to 
metastasize as opposed to the theory that metastasis arises from rare cells 
accumulating metastasis specific genomic alterations in time (Bernards and 
Weinberg, 2002; Ramaswamy et al., 2003). Another explanation for the 
metastatic paradox was revealed from metastatic studies in different genetic 
background in mice. These preliminary studies indicate that the host genetic 
background has a significant role in determining the metastatic potential 
early in oncogenesis (Hunter et al., 2003). 
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2.3 Subclones of MDA-MB-435 cancer cell line as a 
metastasis model 
2.3.1 Origin of the parental MDA-MB-435 cell line? 
 
The MDA-MB-435 cell line was created from malignant cells in a pleural 
effusion of a 31-year old Caucasian woman with breast cancer. Patient had an 
extensive infiltrating breast carcinoma and two of the eight axillary lymph 
nodes contained breast cancer cells. She died one year after her diagnosis 
because of a metastatic disease (Cailleau et al., 1978; Brinkley et al., 1980). 
The origin of the cell line has later been questioned. The microarray data 
and karyotyping show that the cell line has a gene expression pattern most 
compatible with melanocyte origin and identical to the M14 melanoma cells 
that were used as a feeder cell line during the establishment of the MDA-MB-
435 cell line (Ross et al., 2000; Rae et al., 2004; Rae et al., 2007). In support 
of the melanoma origin, the MDA-MB-435 cells were shown to express 
RXRG, TYR, ACP5, and DCP genes, which are commonly transcribed in 
melanocytes but not in various commonly used breast cancer cell lines 
(Ellison et al., 2002).  
However, MDA-MB-435 cells can be induced to express breast 
differentiation markers and secrete milk lipids (Sellappan et al., 2004). They 
also express a number of breast and epithelial cell specific proteins together 
with melanocytic features, most likely due to lineage infidelity (Sellappan et 
al., 2004; Nerlich and Bachmeier, 2013). It is possible that the MDA-MB-435 
cells represent undifferentiated breast cancer and express melanocytic 
differentiation markers since primary breast tumors have been shown to 
express melanocyte related genes (Montel et al., 2009). Furthermore, based 
on karyotype and allelotype, the MDA-MB-435 cells are of female origin and 
cannot therefore be classified as M14 melanoma, which originate from a male 
patient (Chambers, 2009; Hollestelle and Schutte, 2009). 
In respect to the breast cancer molecular subtypes, MDA-MB-435 cell line 
has been classified to represent the basal subtype (Neve et al., 2006; Chavez 
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et al., 2010). It contains a wild-type BRAC1 (Elstrodt et al., 2006) and a 
mutant p53 (Hollestelle et al., 2010; O'Connor et al., 1997).  
2.3.2 Cloning and characterization of the non-metastatic and 
metastatic subclones of the MDA-MB-435 
 
Limiting dilution technique, with direct microscopic monitoring of 
monocellular origin, has been used to create a pair of isogenic clones of the 
MDA-MB-435 cell line. Screening for the metastatic ability in athymic mice 
revealed that these clones significantly differ in in their metastatic capability 
(Urquidi et al., 2002). Both the metastatic and non-metastatic cells are able 
to reach the lungs of tumor-bearing mice thus capable of going through the 
first stage of metastasis, the physical translocation, while only the metastatic 
cells can perform the second phase of metastasis, colonization, in lungs and 
form full-blown metastatic lesions (Goodison et al., 2003). In addition, 
metastatic cells that formed lung metastases could be observed in a dormant 
state in other organs (Suzuki et al., 2006). Thus, these cell lines enable the 
comparative investigation of cellular and molecular events necessary for the 
second phase of metastasis and for the maintenance and subsequent release 
from dormancy at the secondary sites in a stable and isogenic model. 
2.3.3 Identification of metastasis related cell surface proteins 
 
As described earlier, the details and molecular mechanisms of metastasis are 
not fully resolved. At the late stages of metastasis blood flow and other 
mechanical factors influence the delivery of cancer cells to specific organs, 
whereas molecular interactions between the cancer cells and the organ 
influence the probability that the cells will proliferate and grow as a 
metastatic lesion at the new site. Cell surface proteins, the proteins 
protruding from the plasma membrane into the extracellular space, are 
important mediators of these interactions (Place et al., 2011; Bendas and 
Borsig, 2012; Karhemo et al., 2012). Cell surface molecules also represent 
two-thirds of the current protein-based drug targets (Hopkins and Groom, 
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2002; Overington et al., 2006). Some, but not all, cell surface proteins can be 
classified as plasma membrane proteins. For example, ligands bound to their 
surface receptors can be regarded only as cell surface proteins because they 
lack direct contact with the plasma membrane.  
Heterogeneity of tumors and presence of stromal cells within tumors 
hamper the search for cancer cell specific metastasis-associated proteins 
(Hondermarck et al., 2008). Large-scale analysis of cell surface proteins is 
hindered by the poor solubility of hydrophobic, integral membrane proteins. 
Cell surface and membrane proteins are also of low abundant and difficult to 
detect without enrichment or fractionation.  Most cells can be removed from 
tissues, but this is difficult to perform without perturbing the cell surface 
(Leth-Larsen et al., 2010). For these reasons, it is difficult to study these 
proteins in vivo at tissue level. 
The use of isogenic cell lines differing in their metastatic and dormant 
behavior enables identification and functional analysis of candidate proteins 
affecting tumor cell dormancy and metastasis. Cultured cancer cells are easy 
to expand and fractionate and currently provide the best source for the 
analysis of metastasis-associated cell surface proteins in cancer cells. The 
drawback of these models is the lack of proper microenvironment, which has 
been shown to play a crucial role in metastasis. Therefore, expression results 
obtained from the cell line models need further validation in animal models 
and in clinical samples. In addition, mechanistic analyses are required for in 
depth understanding on how these molecules affect the metastatic process. 
Various methods including density gradient centrifugation and numerous 
chemical labeling techniques have been described for the isolation and 
enrichment of the cell surface and/or plasma membrane proteins for 
proteomic analyses (Elschenbroich et al., 2010; Leth-Larsen et al., 2010; 
Cordwell and Thingholm, 2010). Due to their accessibility, cell surface 
proteins of intact cells can be tagged with a membrane-impermeable biotin 
on amino acid residues located in extracellular space, which allows 
exploitation of the extraordinarily stable and non-covalent interaction 
between avidin and biotin in isolation and detection of the biotinylated cell 
surface proteins. Several commercial chemical biotinylation reagents, which 
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vary in their biotin moiety, spacer and reactive moiety, have been developed 
(Elia, 2008). 
Importantly, by using labeling methods, all proteins accessible for the 
labeling reagent e.g., ligands bound to their receptors are isolated and 
analyzed with downstream applications. When adherent cell cultures are 
used as starting material, ECM proteins and secreted proteins bound to their 
ligands or ECM can also be labeled and isolated. Finally, the isolated cell 
surface proteins can be quantified and identified by  proteomics methods to 
revela differentially expressed proteins.  
2.4 Nucleophosmin; oncogene, tumor suppressor or 
both?  
 
Nucleophosmin (NPM, B23, numatrin, NO38, hereafter referred as NPM) is 
a ubiquitously expressed multifunctional nucleolar  phosphoprotein involved 
in a complex network of biological activities related to both growth 
suppression and proliferation. Importantly, it seems that deregulation in 
NPM homeostasis is often observed in tumors. NPM expression and gene 
integrity are frequently altered in human cancers and it has been attributed 
both tumor suppressive and oncogenic functions (Grisendi et al., 2006).  
The human NPM1 gene maps to chromosome 5q35 and contains 12 exons. 
Alternative splicing of the NPM1 transcript results into two isoforms, B23.1 
and B23.2 (Wang et al., 1993). In the full length B23.1 exon 9 is spliced to 
exon 11. The coding sequence stops at exon 12 resulting in a protein 
containing 294 amino acid residues. The shorter B23.2 isoform consists of 
259 amino acids and lacks 35 amino acids at the C-terminus as a result of 
splicing the exon 9 to exon 10, which contains a stop codon. B23.2 is present 
in cells at low levels (Wang et al., 1993).  Circular dichroism spectral analysis 
revealed similar secondary structures (mainly of beta-sheet and beta-turns) 
in B23.1 and B23.2 (Umekawa et al., 1993). Recently a third splice variant 
that lacks an internal exon 8 has been identified in the human EST database 
(GenBank accession number: NM_199185). 
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Figure 2. Functional motifs and domains of NPM/B23. NPM is composed of a non-polar N-
terminal domain containing nuclear export signal (NES). This part of the protein is  important 
for oligomerization and molecular chaperone function. The central  part of the protein 
contains  a two acidic clusters required for histone binding . The  C-terminal domain is 
needed for nucleic acid binding and together with the central region posesses ribonuclease 
activity. Adapted and modified from:(Grisendi et al., 2006). 
The functional motifs and domains of NPM are shown in Figure 2. NPM 
contains motifs for nucleolar localization (Nishimura et al., 2002), nuclear 
import (Hingorani et al., 2000) as well as for nuclear export (Yu et al., 2006; 
Wang et al., 2005). It has distinct N- and C-terminal domains and a central 
part containing two acidic clusters important for NPM’s histone binding 
(Okuwaki et al., 2001)  and ribonuclease activity (Hingorani et al., 2000). 
Importantly, the C-terminal domain of NPM interacts with multiple proteins, 
like p53 (residues 249–262 of NPM) (Lambert and Buckle, 2006), c-Myc 
(residues 187–259 of NPM) (Li et al., 2008), FOXM1 (residues 187-259 of 
NPM) (Bhat et al., 2011) and Akt (residues 239-294 of NPM) (Lee et al., 
2008). In addition, the C-terminal domain (residues 260-294 together with 
Thr199 and Thr234/237) is shown to be responsible for the binding of NPM 
to the phosphorylated RB (Takemura et al., 1999; Lin et al., 2010). Residues 
in parenthesis refer to the different fragments of NPM used to determine the 
binding site. Therefore, the actual binding site might be shorter. In addition, 
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NPM has been reported to bind to a number of other proteins involved in 
cellular processes like DNA replication, transcription, and repair, cell cycle 
control, ribosome biogenesis, viral replication, apoptosis, stability and 
splicing of mRNA, protein modification, mitotic spindle, cytoskeleton, and 
centromeres.  
Notably, most of the functional data on NPM is supported by biochemical 
and in vitro data only. A future challenge is to understand the mechanisms 
which control NPM activation and recruitment to distinct subcellular sites 
and protein complexes to carry out its pleiotropic, often seemingly 
antagonistic, biological functions.  The emerging picture indicates that 
NPM’s biological roles are tightly regulated by several mechanisms such as 
NPM’s expression level, localization, oligomerization status, post-
translational modifications and NPM binding partners.  Cellular distribution 
of NPM is closely associated with phospho/dephosphorylation events (Yun et 
al., 2003) and the nucleolar localization of NPM has been reported to require 
adenosine-5'-triphosphate (ATP) (Chang et al., 1998; Choi et al., 2008; Choi 
et al., 2008).  
NPM undergoes several post-translational modifications, which regulate 
its cellular localization and function. A recent in silico analysis predicted that 
contains 40 potential phosphosites which would be substrates of at least 38 
kinases. Based on the associated kinases the authors suggested that NPM 
phosphorylation is related to cellular processes such as apoptosis, cell 
survival, cell proliferation, and response to DNA damage stimulus (Ramos-
Echazabal et al., 2012), all functions previously attributed to NPM. Post-
translational modifications of NPM are summarized in table 1.  
The following paragraphs summarize the current knowledge on NPM 
regulation and functions relevant to this thesis work. 
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Table 1. Post-translational modifications of NPM 
Enzyme Modification Timing Relevance Ref. 
Plk2 
phosphorylation 
(serine 4) 
S-phase 
Centriole 
duplication 
(Krause and 
Hoffmann, 2010) 
GRK5 
phosphorylation 
(serine 4) 
 
sensitivity of 
cells to PLK1 
inhibition 
(So et al., 2012) 
Unknown 
kinase 
phosphorylation 
(serines 10 and 70) 
 
Regulation of 
CDK1 activity 
(Du et al., 2010) 
CK2 
phosphorylation 
(serine 125) 
interphase 
Dissociation 
from nucleolus 
(Negi and Olson, 
2006) 
 ATR 
phosphorylation 
(serine 125) 
 
Inhibition of the 
UV-induced p53 
phosphorylation 
at Ser15 
(Maiguel et al., 
2004) 
Cyclin B-
CDK1 
phosphorylation 
(threonines 199, 
219, 234, 237) 
mitosis 
Dissociation 
from the 
nucleolus, RNA 
binding, 
centrosomal 
association 
(Peter et al., 
1990; Okuwaki et 
al., 2002; Negi 
and Olson, 2006; 
Cha et al., 2004) 
Cyclin E-
CDK2 
phosphorylation 
(threonine 199) 
G1 
Centrosome 
cycle control 
(Okuda et al., 
2000; Tokuyama 
et al., 2001) 
Cyclin A-
CDK2 
phosphorylation 
(threonine 199) 
S-phase 
and G1 
Centrosome 
cycle control 
(Tokuyama et al., 
2001) 
Cyclin D-
CDK4 
phosphorylation 
(threonine 199) 
G1 
Centrosome 
cycle control 
(Adon et al., 
2010) 
Viral 
cyclin V-
CDK6 
phosphorylation 
(threonine 199) 
 
Kaposi,s 
sarcoma 
herpesvirus 
latency 
(Sarek et al., 
2010) 
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Enzyme Modification Timing Relevance Ref. 
 PKC 
phosphorylation 
(serine 225) 
 
Phosphorylation 
in vitro in 
nuclear 
membrane 
fraction 
(Beckmann et al., 
1992) 
Nek2A phosphorylation mitosis 
Centrosomal 
localization 
(Yao et al., 2004) 
PP1β 
Dephosphorylation 
(threonines 199, 
234, 237) 
 
pRB binding 
and consequent 
E2F1-dependent 
DNA repair 
(Negi and Olson, 
2006; Lin et al., 
2010; Haneji et 
al., 2012) 
SUMO-1 
and 
SUMO-2 
Sumoylation 
 
 
NPM 
localization, 
ribosome 
biogenesis 
(Tago et al., 
2005; Liu et al., 
2007; Haindl et 
al., 2008) 
SENP3 
and 5 
Desumoylation  
Control of 
ribosome 
biogenesis 
(Haindl et al., 
2008; Yun et al., 
2008) 
p300 
Acetylation 
 mostly on the C-
terminal domain) 
 
Stimulation of 
chromatin 
transcription 
(Swaminathan et 
al., 2005) 
BRCA1-
BARD1 
ubiquitin 
ligase 
ubiquitinylation mitosis 
Stabilization of 
NPM 
(Sato et al., 
2004) 
Not 
reported 
poly-(ADP-
ribosyl)ation 
  
(Ramsamooj et 
al., 1995) 
Plk2 = Polo-like kinase,  GRK5 = G protein-coupled receptor kinase 5, 
CK2 = Casein kinase 2, ATR = Ataxia telangiectasia mutated and Rad3 
Related protein kinsase, PKC = Protein kinase C, PP1 β = Protein 
phosphatase 1 β, SUMO =  Small ubiquitin-like modifier, SENP = 
SUMO1/sentrin/SMT3 specific peptidase 
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2.4.1 Discovery of NPM as nucleolar protein involved in ribosome 
assembly and transport 
 
NPM was originally designated as B23 based on its position on a two 
dimensional gel analysis from acid-extracted nucleolar proteins isolated from 
normal rat liver and Novikoff hepatoma ascites cells (Orrick et al., 1973). It 
was shown to be a highly expressed nucleolar phosphoprotein (Kang et al., 
1974; Prestayko et al., 1974), which localizes especially to the granular region 
of the nucleolus, a site where ribosomes are assembled (Spector et al., 1984). 
In addition, NPM was proved to be identical with a nuclear protein numatrin, 
which is tightly bound to nuclear matrix (Feuerstein and Mond, 1987; 
Feuerstein et al., 1988). NPM’s nucleolar localization and its shuttling 
between the nucleus and cytoplasm (Borer et al., 1989) led to the earliest 
proposal that it facilitates ribosome assembly (Dumbar et al., 1989) and 
transport of pre-ribosomal particles (Yung et al., 1985). Later NPM has been 
shown to direct the nuclear export of both 40S and 60S ribosomal subunits 
(Maggi et al., 2008). According to current knowledge, NPM provides the 
necessary export signals and chaperoning capabilities that are required to 
transport ribosome components from nucleus to cytoplasm and by these 
functions it seems to balance protein synthesis to cell growth and 
proliferation (Grisendi et al., 2006; Falini et al., 2007), important 
determinants of cancer growth.  
2.4.2 NPM as a chaperone and its role in transcriptional regulation 
 
Genomic DNA is compacted into chromatin by organizing it into 
nucleosomes by its association with four histone proteins H2A, H2B, H3, and 
H4. The correct assembly/disassembly of nucleosomes is mediated by 
histone chaperones whose precise function is necessary for DNA-dependent 
activities like transcription, replication and repair (Burgess and Zhang, 
2013). 
NPM is biochemically defined as a member of the 
nucleoplasmin/nucleophosmin family of nuclear chaperones. The family 
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members share an acidic core-domain at the N-terminus of the protein which 
is responsible for oligomer formation and chaperone activity (Schmidt-
Zachmann et al., 1987; Hingorani et al., 2000; Frehlick et al., 2007; Okuwaki 
et al., 2001; Prinos et al., 2011). Crystal structure of the N-terminal core 
domain in NPM revealed that it forms pentamers which can further 
oligomerize into decamers similar to the other nucleoplasmin family 
members (Lee et al., 2007). In addition to the N-terminal domain, some C-
terminal regions might be required for NPM oligomer formation (Liu and 
Chan, 1991). A recent computational analysis of the N-terminal domain in 
NPM proposes that NPM monomer-oligomer status can be regulated by 
transformation from a folded, pentameric structure to a monomeric, 
disordered state through phosphorylation events (Mitrea and Kriwacki, 
2012).  
As a nuclear chaperone NPM can bind to histones and assemble 
nucleosomes in vitro (Okuwaki et al., 2001; Gadad et al., 2011). NPM 
possesses chaperone activity also for proteins since it can prevent 
aggregation and thermal denaturation of proteins such as HIV-1 Rev protein, 
liver alcohol dehydrogenase and carboxypeptidase A in vitro (Szebeni and 
Olson, 1999).  
NPM’s histone chaperone activity is enhanced by p300 mediated 
acetylation on the C-terminal domain which modulates in vitro transcription 
from chromatin templates by RNA Pol II (Swaminathan et al., 2005). 
Furthermore, acetylated NPM localizes to nucleoplasm where it regulates 
transcriptional activation of genes implicated in oral cancer manifestation 
such as tumor necrosis factor alpha and interleukin-6 receptor (Shandilya et 
al., 2009). NPM negatively regulates a histone-modifying enzyme GCN5 and 
thus transcription and this regulation was enhanced by phosphorylation of 
NPM at Thr199 (Zou et al., 2008). Recent results indicate that the NPM 
might regulate gene expression at specific G-quadruplex regions (Xu et al., 
2007; Federici et al., 2010; Gallo et al., 2012),  which are common in 
oncogene promoters, whereas a reduced frequency is observed in tumor 
suppressor genes (Qin and Hurley, 2008). NPM has been shown to regulate 
transcription, either positively or negatively, also through interaction with 
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several transcriptional regulatory partners like oncogenic transcription factor 
Forkhead box M1 (FOXM) (Bhat et al., 2011), androgen receptor (Leotoing et 
al., 2008),  activating protein transcription factor 2 (Liu et al., 2007) and YY1   
(Inouye and Seto, 1994), to mention some. Intriguingly, YY1 has also been 
indicated to regulate NPM gene expression (Chan et al., 1997).  
NPM associates with both DNA and RNA with its C-terminal nucleic acid 
binding domain (Wang et al., 1994; Hingorani et al., 2000; Okuwaki et al., 
2002) and it has been reported to have endoribonuclease activity to 
ribosomal RNA (rRNA) (Savkur and Olson, 1998; Hingorani et al., 2000). 
NPM binds to rRNA chromatin and regulates the histone density around 
rRNA genes (Murano et al., 2008). This activity requires NPM’s RNA binding 
activity and is regulated by its cell cycle-dependent phosphorylation (Hisaoka 
et al., 2010). 
The B23.2 splice variant of NPM lacks the C-terminal domain and 
therefore is not able to bind double stranded DNA (Wang et al., 1994) and 
has lower ribonuclease activity than the full-length NPM protein (Herrera et 
al., 1995). In addition, B23.2 can heterodimerize with the full length NPM 
and reduces its RNA-binding (Okuwaki et al., 2002). Oligomer formation by 
itself has also been shown to decrease NPM’s DNA binding (Herrera et al., 
1996). 
2.4.3 Molecular pathways regulated by NPM: RB, ARF-p53-Mdm2 
pathway and c-Myc  
 
The retinoblastoma protein (RB), encoded by the RB1 gene, is the first known 
human tumor suppressor (Knudson, 1984; Corson, 2007; Dimaras, 2008; 
Huang et al., 1988) which is inactivated in multitude of solid cancers by 
various distinct mechanisms (Burkhart and Sage, 2008). In normal quiescent 
tissues RB maintains cell cycle arrest by repressing the activity of E2F-family 
of transcription factors (E2F1, E2F2, and E2F3) (Burkhart and Sage, 2008; 
Cobrinik, 2005). This repression is relieved by mitogenic or oncogenic 
signals, which induce RB phosphorylation (pRB) (Mittnacht, 1998). As a 
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consequence, the expression of genes involved in DNA-replication, mitosis 
and cytokinesis is induced (Markey et al., 2007).   
Hyperphosphorylated RB translocates into nucleoli in late S or G2 phase. 
Translocation is mediated by NPM (Takemura et al., 1999; Takemura et al., 
2002), most likely after dephosphorylation of NPM on threonines 199, 234, 
237 by PP1β (Lin et al., 2010). The biological significance of the pRB-NPM 
complex and nucleolar localization is unclear but RB and NPM have been 
shown to synergistically stimulate DNA polymerase alpha activity (Takemura 
et al., 1999).  
The p53 tumor supressor gene is defective in about half of all tumors, 
regardless of their type or origin (Hollstein et al., 1991; Levine et al., 1991) 
and in the remaining cancers a considerable number has alterations in the 
p53 pathway. The p53 gene encodes a tetrameric protein that functions 
mainly as a transcription factor at the crossroads of cellular stress response 
pathways (like DNA damage, oncogene activation and hypoxia) controlling 
the expression of genes involved in cell division and viability, growth arrest 
and apoptosis (Levine and Oren, 2009). NPM regulates p53 by directly 
binding to it (Colombo et al., 2002; Maiguel et al., 2004) and by affecting the 
p53 regulatory proteins ARF (Bertwistle et al., 2004; Korgaonkar et al., 
2005) and Mdm2 (Kurki et al., 2004). NPM has a dual effect on p53 and it 
can either stabilize (Colombo et al., 2002; Horn and Vousden, 2004; Kurki et 
al., 2004) or inhibit p53 (Li et al., 2004; Wu et al., 2002; Dhar and St Clair, 
2009; Li et al., 2007) and apoptosis. Mechanisms regulating such opposite 
effects are mainly unknown. NPM oligomerization might be  necessary for its 
capability to inhibition p53-mediated apoptosis (Qi et al., 2008; Jian et al., 
2009). NPM could also inhibit p53 activity by competing with p53 
phosphorylation (Maiguel et al., 2004; Nalabothula et al., 2010). NPM 
binding partners have also been reported to regulate its effect on p53 (Ji et 
al., 2012; Fukawa et al., 2012). 
The small tumor suppressor protein p14ARF (humans, p19ARF in mouse, 
hereafter referred as ARF ) functions as a tumor suppressor by inhibiting the 
Mdm2 mediated degradation of p53. It binds directly to Mdm2 in a site 
distinct from the p53 binding domain (Ashcroft and Vousden, 1999) which 
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inhibits the ubiquitin ligase activity of Mdm2 (Honda and Yasuda, 1999). 
Even though the complex interaction between ARF and NPM has been under 
extensive investigation over the last years, it is still not fully understood. 
NPM binds ARF in the nucleoli in a quantitative manner (Bertwistle et al., 
2004). ARF mutants lacking the NPM binding site are unstable (Kuo et al., 
2004) and ARF localizes to nucleoplasm in MEFs lacking both p53 and NPM 
(Colombo et al., 2005) indicating that NPM stabilizes ARF in the nucleoli. On 
the other hand, ARF has been shown to mediate NPM degradation (Itahana 
et al., 2003) indicating a feed-back loop between these two proteins. ARF has 
also been shown to block NPM function in rRNA processing and the 
transport of pre-ribosomal particles (Savkur and Olson, 1998; Itahana et al., 
2003; Sugimoto et al., 2003; Brady et al., 2004). NPM is also a target for 
ARF induced sumoylation (Tago et al., 2005). 
c-Myc induces both p53-dependent and p53-independent apoptosis upon 
up-regulation of the tumor suppressor ARF. However, when overexpressed 
or deregulated c-Myc becomes oncogenic (Hoffman and Liebermann, 2008; 
Nilsson and Cleveland, 2003). Importantly, in animal models, most if not all, 
c-Myc-induced tumors have inactivated the ARF-p53 pathway (Eischen et al., 
1999; Nilsson and Cleveland, 2003).There is a complex interaction between 
NPM and the c-Myc-oncogene. Expression of c-Myc correlates with NPM 
expression (Guo et al., 2000; Neiman et al., 2001; Kim et al., 2000) and 
NPM is a transcriptional target of c-Myc (Zeller et al., 2001). In addition, 
NPM directly interacts with c-Myc and regulates c-Myc mediated rDNA 
transcription, nucleolar localization (Li and Hann, 2013) and expression of c-
Myc target genes like eIF4E (Li et al., 2008). NPM overexpression has been 
shown to enhance c-Myc-induced proliferation and transformation in p53-/- 
ARF-/- double knockout (DKO) mouse embryo fibroblasts (MEFs) (Li et al., 
2008) 
 Recent studies, however, have shown that NPM binds to the G-
quadruplex DNA on c-Myc gene-promoter which suppresses c-Myc gene 
expression (Siddiqui-Jain et al., 2002; Gallo et al., 2012). In addition, 
Reduction in NPM levels accelerated lymphomagenesis in μ-Myc transgenic 
mice (Grisendi et al., 2005).  
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Figure 3. Schematic representation of the discussed pathways controlled by NPM. Solid 
lines indicate connections with strong scientific backround.  
2.4.4 Role of NPM in centrosome duplication  
 
Centrosomes, the microtubule-organizing centers of animal cells, are mainly 
composed of mother and daughter cylindrical microtubule-based centrioles 
and a matrix of associated pericentriolar material. Centrosome is duplicated 
in coordination with DNA replication. Centrosome amplification is 
frequently observed in cancers and is postulated to be one cause of 
chromosome instability. Proper centrosome function is also required for 
cytokinesis (Wang et al., 2004; Zyss and Gergely, 2009).  
Cultured NPM-null cells or mice carrying a single inactivated Npm1 allele 
display increased centrosome numbers (Grisendi et al., 2005). In 
accordance, NPM is shown to control centrosome cycle. NPM attaches to 
single, unduplicated centrosomes in late G1 (Ochs et al., 1983) and re-
associates with the centrosomes during mitosis (Zatsepina et al., 1999; 
Okuda et al., 2000) at least partly after its phosphorylation on Thr234 and 
Thr237 by cyclin B-CDK1 complex (Cha et al., 2004). At the centrosome, 
NPM localizes between the centriole pair (Shinmura et al., 2005). Cyclin 
E(A)-CDK2 (Tokuyama et al., 2001; Okuda et al., 2000) and cyclin D-CDK4 
phosphorylate NPM at Thr199, which partly dissociates NPM from the 
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centrosome subsequently allowing separation of the centrioles and 
centrosome duplication (Okuda et al., 2000; Tokuyama et al., 2001; Okuda, 
2002; Tarapore et al., 2002).  
Some NPM phosphorylated on Thr199 remain attached to centrioles, 
translocates toward a mother centriole (Shinmura et al., 2005) and binds to 
and activates centrosomal ROCK II kinase, which further promotes 
centrosome duplication (Ma et al., 2006). In addition to Thr199 
phosphorylation, Plk2-mediated phosphorylation of NPM on serine 4 has 
been shown to promote centrosome duplication (Krause and Hoffmann, 
2010). However, while  important in regulating the correct centrosome cycle, 
the Thr199 phosphorylation might not be necessary for NPM’s growth 
promoting functions (Brady et al., 2009).  
 
2.4.5 NPM in human tumors and in mice 
 
NPM protein levels are elevated in rapidly dividing cells (Feuerstein and 
Mond, 1987; Feuerstein and Mond, 1987; Nozawa et al., 1996) and its 
expression increases rapidly in the early G1 phase during mitosis (Feuerstein 
et al., 1988) which led to the proposed growth promoting function of NPM. 
In accordance, NPM levels decrease in cells that are withdrawn from the cell 
cycle or undergoing apoptosis (Hsu and Yung, 1998; You et al., 1999; Yung, 
2004). NPM expression associates with poor prognosis, recurrence or lymph 
node metastasis in Ewing’s sarcoma (Kikuta et al., 2009), bladder carcinoma 
(Tsui et al., 2008), colon cancer (Liu et al., 2012) and oral squamous cell 
carcinoma (Coutinho-Camillo et al., 2010) in a relative small patient 
materials (n=31-154). In hematological malignancies NPM is involved in 
chromosome translocations, where its N-terminal oligomerization domain is 
fused with different partners like ALK, RARα and MLF. NPM 
oligomerization domain contributes to tumor development by activating the 
oncogenic potential of the fused protein partner (Grisendi et al., 2006).  
On the contrary, Bocker and coworkers did not find difference in NPM 
expression between normal and malignant epithelial prostatic cells (Bocker 
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et al., 1995) and NPM expression did not correlate with patient prognosis in 
an analysis of 55 melanoma patient samples (Calli et al., 2011). No 
amplification of NPM1 has been detected in human tumors, but deletion of 
the gene has been observed in non-small cell lung carcinomas (Mendes-da-
Silva et al., 2000). In addition, NPM1 is the most frequently mutated gene in 
acute myeloid leukemia (AML) accounting for ∼35% of cases (Falini et al., 
2005). Mutations in the C-terminal domain lead to mutant proteins that 
aberrantly and stably localize to the cytoplasm due to an additional nuclear 
export signal at the C-terminal domain (Bolli et al., 2007; Albiero et al., 
2007). Mutant NPM oligomerizes with the wild type protein, which is also 
transported to the cytoplasm thus functioning as a dominant negative (Falini 
et al., 2009). These mutations seem to represent tumor –initiating lesions, 
since they appear before the other AML-associated genetic alterations can be 
detected (den Besten et al., 2005).  
Npm1 acts as a haploinsufficient tumor suppressor in the hematopoietic 
compartment in mice (Sportoletti et al., 2008). Inactivation of Npm1 in the 
germ line leads to embryonic lethality in mice at midgestation indicating 
indispensable role during development (Colombo et al., 2005; Grisendi et al., 
2005). Npm1 null embryos display genomic instability, widespread 
apoptosis, and activation of p53. In addition, cultured NPM-null cells or mice 
carrying a single inactivated Npm1 allele  accumulate DNA damage (Colombo 
et al., 2005) and have increased centrosome numbers (Grisendi et al., 2005). 
In addition, Npm1+/− MEFs have an immortal phenotype with noticeably 
high proliferation rates (Colombo et al., 2005; Grisendi et al., 2005) and 
display accelerated lymphomagenesis when crossed with μ-Myc transgenic 
mice (Grisendi et al., 2005). 
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3 AIMS OF THE STUDY 
Cell surface proteins are known to be important players in regulating cancer 
metastasis. As the molecular mechanisms underlying the second phase of 
metastasis (colonization at the distant site) and metastatic dormancy are 
poorly resolved, we wanted to identify novel cell surface proteins 
contributing to colonization at the distant site. The aim was not to gain a 
comprehensive picture of the cell surface proteins of the two cell lines used 
but to identify differentially expressed proteins for future studies. 
 
The specific aims included: 
 
 Isolate the cell surface proteins from invasive, non-metastatic and 
fully metastatic cell clones of the MDA-MB-435 cell line for a 
proteomic based comparative study  
 Profile the differential expression of cell surface proteins in order to 
discover interesting, differentially expressed proteins for future 
functional studies in metastatic colonization 
 Analyze the breast cancer associated role and function of one of the 
identified proteins, nucleophosmin, in more detail 
MATERIALS AND METHODS 
40 
4 MATERIALS AND METHODS 
 
 
Figure 4. Flowchart of the study 
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The materials and methods of this study are listed in table 2.  with detailed 
descriptions in the following text and in the original publications, here 
referred to by Roman numerals. 
 
Table 2. Methods used in the study  
Methods Used in 
Cell proliferation assays II, III 
 Cell surface biotinylation I, unpublished data 
Cloning  II, III 
Creation of stable cell lines II, III 
Gene knockdown by RNA interference  III 
Immunofluorescence microscopy I, II, III, unpublished data 
Immunohistochemistry I, II, III 
Immunoprecipitation II, III 
Implantation of tumor cells into mice I 
Lentiviral production II 
Mammalian cell culture I, II, III 
Mass spectrometry based protein identification I, unpublished data 
Network and pathway analyses II 
Quantitative real-time PCR II 
RNA extraction II, III 
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Methods Used in 
Scoring of tumor microarrays II, III 
SDS-PAGE and immunoblotting I, II, II, unpublished data 
Sequence analysis II, III 
Soft agar assay II 
Statistics I, II, III 
Transduction of mammalian cells  II 
Transfection of mammalian cells II, III 
3D cell culture II 
17β-Estradiol Treatment II 
4.1 Cell culture (2D and 3D), cell treatments, cell 
proliferation and soft agar assays 
 
Human cancer cell lines (Table 1) were cultured at + 37 °C in 5% CO2 
atmosphere in appropriate medium. For 3D growth/invasion assays cross-
linked fibrin gels were prepared by combining 75 µl plasminogen-free human 
fibrinogen (6 mg/ml; Calbiochem) in Hank's Balanced Salt Solution (HBSS) 
and 75 µl HBSS (pH 7.4) containing 4 U/ml human thrombin and 400 µg/ml 
aprotinin (both from Sigma-Aldrich). 5000 cells were suspended in 40 µl of 
the prepared, cross-linked fibrin and transferred to a 24-well plate. The plate 
was incubated for 1 h at 37°C to allow complete gelling. The cells were grown 
for 4–16 days, fixed and photographed 
For the 17β-Estradiol Treatment cells were starved for 48 hours in Phenol 
Red-free RPMI (Gibco, California, USA) supplemented with 2% charcoal-
dextran filtrated fetal calf serum (HyClone; Thermo Scientific, Logan, UT), 
1% glutamine, and penicillin-streptomycin. Starved cells were treated with 10 
nmol/L 17β-estradiol for 3 days and analyzed.  
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Cell proliferation was measured by growing cells on 96-well plates for 
indicated time periods. Cells were incubated 2 hours with 10 μL MTT (5 
mg/mL) and lysed (10% SDS, 10 mmol/L HCl) overnight. Absorbance was 
measured at 540 nm using Multiskan Ascent software version 2.6 (Thermo 
Labsystems, Vantaa, Finland). 
For Soft agar assays tissue culture dishes containing a 2-mL layer of 
solidified 0.7% agar in a complete medium were prepared.  Cells (5 × 103 
cells per 35-mm well) were suspended in complete medium containing 
0.35% agarose and plated on top of the solidified bottom agar. After 14 days, 
number of colonies was quantified. For visualization, foci were methanol-
fixed and stained with 0.005% crystal violet. 
4.2 Cell surface protein isolation  
 
Cells were grown 3 days after which they were washed three times with 
Dulbecco (PBS + 0.901 mM CaCl2 + 0.492 mM MgCl2) and labeled with EZ-
Link Sulfo-NHS-SS-Biotin (Pierce, Rockford, IL, USA; 0.5 mg/ml in) for 30-
minutes in Dulbecco on ice. Labeling solution was removed by washing the 
cells twice with Dulbecco followed by blockade of the non-reacted biotin with 
20 mM glycine for 15 minutes and washed with Dulbecco + 100 μM oxidized 
glutathione (Sigma-Aldrich, St. Louis, MO). Cells were lysed and the 
membrane proteins solubilized in 500 μl of lysis buffer (PBS + 2% NP-40, 1% 
Triton X-100, 10% glycerol, 100 μM oxidized glutathione, EDTA free 
protease inhibitor tablet (Roche, Mannheim, Germany)) for 30 minutes. The 
cell extracts were incubated with 30 U of DNase (22 °C 50 min, Roche, 
Mannheim, Germany) and centrifuged for 20 min (20 800 ×g, at + 4 °C). 
Equal amounts of protein from each cell extract, determined by DC- (Bio-
Rad, Hercules, CA, USA) or BCA- (Thermo Fisher Scientific, Pierce Rockford, 
IL, USA) protein assays were used for cell surface protein isolation. The 
supernatant was pre-cleared using biotin agarose beads (ImmunoPure® 
Immobilized D-biotin, Pierce, Rockford, IL, USA) and incubated with 
magnetic streptavidin beads (Dynabeads®MyOne™ Streptavidin, Invitrogen 
Dynal, AS, Norway). Beads were washed four times with the lysis buffer, four 
times with 300 mM NaCl in lysis buffer and twice with 50 mM Tris–HCl, pH 
7.8. and the isolated proteins were eluted with 50 mM DTT in 50 mM Tris–
HCl, pH 7.8 at 30 °C, followed by pooling of the eluates. 
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4.3 Mass spectrometry, protein identification, network 
and pathway analyses 
 
For LC–MS/MS analysis proteins were digested with trypsin (sequence grade 
modified, Promega, Madison, WI, USA) and peptides were loaded to a 
reversed phase pre-column (NanoEase Atlantis dC18, 180 μm × 23.5 mm, 
Waters, Milford, MA, USA) with 0.1% formic acid followed by separation in 
reversed phase analytical column (PepMap 100, 75 μm × 150 mm, Thermo 
Fisher Scientific Dionex, Germerin, Germany) with a linear gradient (4–
50%) of 95% acetonitrile in 0.08% formic acid in 35 min. Full scan for eluting 
peptides was acquired in an LTQ Orbitrap XL mass spectrometer (Thermo 
Fisher Scientific Inc.) introduced to via the ESI Chip interface (Advion 
BioSciences Inc.) in the positive-ion mode. The mass range of 300–
2000 m/z on the Orbitrap-detector with 60 000 resolution (FWHM) at 
400 m/z, the AGC target was set to 200 000 and the maximum inject time to 
800 ms. Six MS/MS data-dependent scans were acquired on LTQ based on 
full scan, with the AGC target set to 10 000 and the maximum inject time set 
to 100 ms. An isolation width of 2 m/z was used for precursor selection. 
Peptide fragmentation was done in normalized collision energy of 35%, 
activation time of 100 ms and activation Q set to 0.25. Precursors, whose 
charge state couldn't be determined or charge state was + 1, were discarded 
from the MS/MS analysis. Precursors were dynamically excluded for 10 s 
with a repeat count of 1. Both full scan and MS/MS scans consisted of one 
microscan and they were acquired as profile data. 
Mascot (version 2.2, in-house server), Swissprot 2010 (516 080 
sequences, 181 677 051 residues) and the following parameters were used for 
protein identification: enzyme: trypsin, peptide mass tolerance: 0.02 Da, 
fragment mass tolerance 0.8 Da, max missed cleavages 2, variable 
modifications: carbamidomethy (C), carboxymethyl (C), deamidated (NQ), 
oxidation (M), propionamide (C), and pyridylethyl (C). Same search was also 
conducted limiting the taxonomy to human, except using variable 
modifications carbamidomethyl (C), oxidation (M), and propionamide (C). 
Both results were combined and the results filtered to human proteins. 
Mascot score > 40 was required for identifications in the total protein list. In 
addition, at least one unique peptide was required for the reported 
differentially expressed proteins. Pathway and network analyses for the 
differentially expressed proteins were performed in a computational platform 
Moksiskaan. 
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4.4 Immunoprecipitation and immunoblotting 
  
Equal amounts of protein from post nuclear supernatans of each extract were 
pre-cleared using protein G sepharose™ 4 fast flow beads (GE Healthcare 
Bio-Sciences Ab, Uppsala, Sweden) followed by incubation with the 
appropriate antibodies (+ 4 °C, o/n). The antibody-antigen complex was 
captured on G sepharose beads (+ 4 °C, 30 min), which were washed four 
times with lysis buffer and boiled in Laemmli buffer. 
Proteins were separated using SDS-PAGE and transferred to Immobilon-
P Membrane (Millipore, Bedford, MA, USA). Immunoblots were incubated 
with the appropriate primary and secondary antibodies (HRP conjugated, 
Dako, Glostrup, Denmark) followed by enhanced cemiluminecense 
visualization using the SuperSignal West Pico kit (Thermo Fisher Scientific, 
Pierce, Rockford, IL, USA). 
4.5 Immunohistochemistry and immunofluorescence 
analyses 
 
For immunofluorescence staining of intracellular antigens, cells were fixed 
with 4% paraformaldehyde and permeabilized with 0.5% NP-40 in PBS. 
Unspecific antibody binding sites were blocked using 3% bovine serum 
albumin in PBS. The cells were incubated with primary and secondary 
(Molecular Probes goat anti-mouse Alexa Fluor 594; Invitrogen, Carlsbad, 
CA) antibodies. For staining of cell surface antigens live cells were blocked 
and incubated with the primary antibodies on ice after which they were fixed 
and incubated with the secondary antibodies.  DNA was visualized with DAPI 
(Vector Laboratories, Burlingame, CA). 
For the immunohistochemical analyses paraffin embedded sections were 
deparaffinized and the antigens retrieved with the appropriate method for 
each antibody. Primary antibodies were detected by using the TSA-kit 
(Perkin Elmer, Waltham, MA, USA) and the signal was visualized with the 
AEC-reagent (Sigma-Aldrich, St. Louis, MO) or by using peroxidase staining 
(biotinylated horse anti-mouse immunoglobulins 1:200 and Vectastain ABC 
complex; Vector Laboratories), which was visualized with 3,3′-
diaminobenzidine (Vector Laboratories). Images were captured with an 
Olympus DP50 camera and with Olympus Studio Lite software version 1.0 or 
1.01. For the C-kit staining we used PowerVision Novocastra preantibody 
blocking solution (Leica Microsystems, Wetzlar, Germany) for primary 
antibody incubation. Staining was detected using a PowerVision + Poly-HRP 
histostaining kit (DPVB + 110DAB; ImmunoVision Technologies, Daly City, 
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CA; Springdale, AR) according to the manufacturer's instructions. A Ventana 
Discovery IHC slide stainer (Ventana Medical Systems, Tucson, AZ) and a 
Ventana 3,3′-diaminobenzidine tetrahydrochloride biotin avidin detection 
kit was used for  the cytokeratin staining. 
 
4.6 Patients and classification of breast cancer 
subtypes in the TMAs 
 
We used two different breast cancer patient cohorts, the FinProg and FinHer, 
which both contained detailed clinical information allowing survival and 
association analyses. The cancers were classified into five biological subtypes 
as follows; luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or 
PR+, HER2+), basal-like (ER-, PR-, HER2-, CK5+ and/or EGFR+), HER2-
enriched (HER2+, ER-, PR-), and non-expressor type (negative for all five 
key classifiers). The non-expressor type corresponds to unclassifiable triple-
negative breast cancer.  An ethics committee at Helsinki University hospital 
approved the FinHer study. Regarding FinProg material permission to use 
formalin fixed paraffin embedded tissues for research purposes was provided 
by the Ministry of Social Affairs and Health, Finland. 
4.7 Statistical analyses 
 
In the TMAs the associations between factors were tested with the χ2 test. 
The odds ratio was used to examine the strength of the relationships. Kaplan-
Meier method was applied to calculate the life tables. Multivariate survival 
analyses were performed with the Cox proportional hazards model, entering 
the appropriate covariates. 
Progenesis LC–MS software was used to quantitate the expression 
differences in the comparative proteomic analysis. The runs were divided 
into following 4 groups; metastatic and non-metastatic non-biotinylated 
controls and metastatic and non-metastatic samples. The peptides present in 
control groups, determined by manual comparison of the peptides, were 
discarded form the analysis followed by comparison of the metastatic and 
non-metastatic samples against each other. ANOVA and q-values calculated 
by the Progenesis software were used to deduce differentiating peptides. The 
Progenesis stats‐package was used to perform unsupervised principal 
component analysis (PCA). 
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5 RESULTS AND DISCUSSION 
5.1 Comparative analysis of metastasis and dormancy 
associated cell surface proteins (I and unpublished 
data) 
 
As described earlier, the details and molecular mechanisms of metastasis are 
not fully resolved. Therefore, we wanted to identify novel cell surface 
proteins contributing to the formation of metastasis, especially to the second 
phase (colonization at the distant site). In this thesis work we used metastatic 
and non-metastatic subclones of the MDA-MB-435 human carcinoma cell 
line as a model for the metastatic spread of cancer. The non-metastatic cells 
leave the primary tumor as efficiently as the metastatic ones and are detected 
as single cells in the lung capillaries.  However, they fail to go through the 
latest steps of the metastatic cascade and cannot form full- blown metastases 
(Goodison et al., 2003).  
Originally, this thesis work aimed at comparing the differences in cell 
surface proteins between the metastatic and non-metastatic cell pair by using 
two-dimensional (2D) gel electrophoresis. (Karhemo et al., unpublished 
data). However, the fast development of gel-free shotgun proteomics 
technologies (Duncan et al., 2010)  and mass spectrometry based protein 
quantification (Ong and Mann, 2005; Domon and Aebersold, 2010)  led us to 
analyze and quantify our isolated cell surface samples using liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) (Study 
I). 
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5.1.1 Optimized method for isolation of biotinylated cell surface 
proteins (I) 
 
For comparative proteomic analysis the cell surface proteins of the isogenic 
non-metastatic and metastatic cell pair were labeled with biotinylation 
reagents that react with primary amines (-NH2), such as the side-chain of 
lysine followed by isolation with magnetic streptavidin beads.  
Studies used as reference to optimize the isolation of biotinylated cell 
surface proteins reported a consistent identification of intracellular proteins 
(Scheurer et al., 2005; Roesli et al., 2008). To diminish this intracellular 
background the cell extracts were treated with DNAseI to dissolve the 
cytosolic actin and proteins associated with it from the viscous DNA in order 
to liberate a maximal amount of membrane proteins. In addition, samples 
were pre-cleared by using biotin agarose beads and intracellular background 
was controlled by including non-biotinylated control samples in the analysis.  
The gel-free LC-MS/MS approach resulted in identification of 86 proteins 
in total from both cell lines. This relatively limited number of identifications 
might be explained by performance of database search within the Progenesis 
LC–MS software after exclusion of all peptides present in the control 
samples, by the low amount of starting material and the performance of the 
LC–MS analyses without exclusion lists to exclude already fragmented 
features.  
Importantly, more than 60% of the identified proteins localized to the cell 
surface/extracellular space according to the Finnish Red Cross in house Cell 
Surface Protein Classifier. The specific enrichment of cell surface proteins 
was further verified by analyzing the presence of a cell surface protein, 
cluster of differentiation 109 (CD109), the endoplasmic protein BiP, the Golgi 
protein Golgin 97, the subunit IV of mitochondrial protein cytochrome C 
oxidase and an intracellular protein Erk1/2 in the cell surface and unbound 
fractions (representing proteins that did not bind to the streptavidin beads) 
in a Western blot analysis. Our optimized protocol specifically isolated the 
cell surface proteins since that fraction was free of organelle contaminants 
(Figure 1A and B in publication I).  
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5.1.2 Cell surface protein changes in the metastatic cells (I, 
unpublished data) 
 
This thesis work revealed 29 differentially expressed proteins (Table 3) from 
the cell surface samples between the metastatic and non-metastatic cells 
using the 2D gels (Karhemo et al, unpublished results) and the LC-MS/MS 
analyses (publication I). Six differentially expressed proteins were identified 
from silver stained 2D gels based on visual comparison of the spot intensities 
(Table 3). The gel-free analysis revealed 23 differentially expressed proteins 
(Table 3, Table 1 in publication I).   
Based on a Uniprot database (http://www.uniprot.org/) annotation and 
literature search 19/29 proteins (66%) represented proteins with known cell 
surface localization. The gel-free LC-MS/MS based approach proved to be 
superior in identifying cell surface membrane proteins compared to the 2D 
gels. Only one protein, LGALS3, identified using the 2D gels is reported to be 
secreted to the cell surface and only one protein is predicted to contain a 
single transmembrane domain. On the contrary, 18/23 (78%) of the 
differentially expressed proteins identified in the gel-free analysis 
represented proteins with previously reported cell surface localization and 15 
were either single or multi-pass transmembrane proteins (Table 3). 
 Interestingly, most of the identified proteins (20/29, 69%) were 
overexpressed in the metastatic cells. Similar results have been obtained in a 
previous proteomic analysis of ultracentrifuged and density separated 
plasma membrane fractions of the same isogenic MDA-MB-435 cancer cell 
pair (Lund et al., 2009). These results indicate that 
overexpression/localization of certain proteins on the surface of the 
metastatic cells may facilitate extravasation and colonization of the 
metastatic cells by adapting them to the new microenvironment at the 
secondary site.  
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Table 3. Differentially expressed proteins identified in the thesis work 
Name 
Relative  
expression 
(metastatic/non-
metastatic) in LC-
MS/MS 
Method 
Cellular 
localizationA 
Type of 
membrane 
protein 
MRPL12  2D 
mitochondrion, 
ribosome 
 
RPLP0  2D 
cytoplasm, 
ribosome 
 
MRPL39  2D 
mitochondrion, 
ribosome 
 
NPM  2D 
nucleolus, 
nucleus 
 
SSR4  2D 
endoplasmic 
reticulum 
membrane 
single-pass  
LGALS3  2D 
secreted, 
cytoplasm, 
nucleus  
peripheral 
HLA-
DRB1 
 8.8 
LC-
MS/MS 
cell membrane single-pass  
HLA-
DRA1 
2.53 
LC-
MS/MS 
cell membrane single-pass  
BST2 7.88 
LC-
MS/MS 
cell membrane, 
trans-Golgi 
network 
single-pass, 
GPI-anchor 
PTGFRN 7.44 
LC-
MS/MS 
cell membrane single-pass  
ART3 6.03 
LC-
MS/MS 
cell membrane GPI-anchor 
PROCR 4.4 
LC-
MS/MS 
cell membrane single-pass  
GPR56 3.01 
LC-
MS/MS 
cell membrane multi-pass  
ADAM10 2.74 
LC-
MS/MS 
cell membrane single-pass  
PTPRF 2.4 
LC-
MS/MS 
cell membrane single-pass  
ATP1B3 2.21 
LC-
MS/MS 
cell membrane single-pass  
CD109 2.11 
LC-
MS/MS 
cell membrane GPI-anchor 
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Name 
Relative  
expression 
(metastatic/non-
metastatic) in LC-
MS/MS 
Method 
Cellular 
localizationA 
Type of 
membrane 
protein 
ITGA6 2.08 
LC-
MS/MS 
cell membrane single-pass 
TUBA1C 2.01 
LC-
MS/MS 
cytoplasm, 
cytoskeleton 
 
IGSF8 2 
LC-
MS/MS 
cell membrane single-pass  
ITGAV 1.82 
LC-
MS/MS 
cell membrane single-pass  
HSPD1 1.76 
LC-
MS/MS 
mitochondrion 
matrix 
 
FASN 1.7 
LC-
MS/MS 
cytoplasm  
ITGB1 1.44 
LC-
MS/MS 
cell membrane single-pass  
GOT2 0.43 
LC-
MS/MS 
mitochondrion 
matrix, cell 
membrane 
peripheral 
NME1 0.49 
LC-
MS/MS 
cytoplasm, 
nucleus 
 
CHL1 0.56 
LC-
MS/MS 
cell membrane single-pass  
CD97 0.73 
LC-
MS/MS 
cell membrane multi-pass  
ALDH7A1 0.75 
LC-
MS/MS 
mitochondrio, 
nucleus 
 
 Overexpressed, underexpressed (metastatic/non-metastatic) 
A UniProt and literature  
Proteins that displayed ≥ 2-fold in their expression are underlined, proteins whose 
differential surface expression was validated by antibodies are highlighted. 
 
Previous gene array analysis, which compared a subclone of the original 
metastatic MDA-MB-435 clone to the non-metastatic one, revealed 
overexpression of vesicular trafficking related genes (Rab27, Rab38, VAMPA 
and syntaxin 7) in the metastatic cells. Rab27 and Rab38 are small GTPases 
functioning at various stages of vesicular fusion and trafficking.  The vesicle-
associated membrane protein-associated protein A (VAMPA) and syntaxin 7 
mediate the fusion of organelle membranes and vesicle attachment to 
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lysosomes, (Montel et al., 2005; Steeg, 2005). Overexpression of these 
proteins could partly explain the observed upregulation of cell surface 
proteins in the metastatic cells. However, when using the cell surface 
biotinylation method, detergents used to solubilize the membrane proteins 
influence the type of proteins that will be identified with the downstream 
applications as only the proteins soluble in the detergent will be isolated and 
identified.  Other comparatice proteomic analyses of biotinylated cell surface 
fractions from paired non-metastatic and metastatic cells have reported 
different ratios (Conn et al., 2008; Roesli et al., 2009; Luque-Garcia et al., 
2010).  In this thesis work, only one detergent combination (2% NP-40, 1% 
Triton X-100, 10% glycerol) was used and therefore many proteins insoluble 
in this buffer were naturally excluded from the analysis. The number of 
differentially expressed proteins could therefore be increased by using 
various different detergents, which might also affect the relative numbers of 
up and downregulated proteins between the cell pair.  
5.1.3 Validation of the differential cell surface expression of selected 
proteins (I, unpublished data) 
 
In order to validate the differential expression and/or localization of the 
identified proteins we used Western blot and immunofluorescence analyses. 
In regards of the LC-MS/MS results, higher expression of PROCR 
(endothelial protein C receptor), CD109 and ITGA6 (integrin-α6) on the 
surface of the metastatic cells was confirmed (Figure 3A and B in publication 
I). Integrin β1 (ITGB1), which displayed only a 1.4-fold expression difference 
in the LC-MS/MS quantitation was used as a control. According to Western 
blot and immunofluorescence analyses it was expressed at equal levels at the 
cell surface of the cell pair (Figure 3A and B in publication I). In addition, the 
differential expression of two proteins, SSR4 and NPM, which were over- and 
under expressed at the metastatic cell surface in the 2D analysis, respectively, 
was validated in the cell surface samples. (Figure 5A, Karhemo et al, 
unpublished results).  
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Figure 5. Analysis of SSR and NPM expression in the non-metastatic and metastatic cells. 
A) Expression of SSR4 and NPM in the metastatic and non-metastatic cells was detected 
using Western blot analysis of cell surface extracts. Expression of NPM was also analyzed 
from the unbound fraction representing intracellular NPM levels. B) Immunofluorescence 
analysis of NPM using antibodies against NPM followed by an Alexa-594 conjugated 
secondary antibody. Non-metastatic and metastatic cells showed equal nuclear NPM 
staining. However, the metastatic cells displayed an additional cytoplasmic staining in some 
cells. Nuclei were visualized with DAPI (blue). Images were digitally cropped in Photoshop 
CS4. 
Since the differential expression at the cell surface could result either from 
differences in the expression levels or from differential localization of 
proteins we analyzed the expression of CD109 and PROCR in whole cell 
extracts and NPM in the unbound fractions. No difference in the expression 
level of NPM was detected (Figure 5A, Karhemo et al., unpublished results) 
while both PROCR and CD109 were expressed at higher levels in the 
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metastatic cell line compared to the non-metastatic cells (Figure 3A in 
publication I).Importantly, this indicates that a change of NPM localization 
might play a role in metastatic colonization. Metastasis associated decrease 
in cell surface expression of NPM has also been reported in another cell 
surface proteomics study (Roesli et al., 2009). To analyze NPM cellular 
localization in more detail in our isogenic cell lines, we stained fixed and 
permeabilized cells with anti-NPM/B23 antibodies. Interestingly, in both cell 
lines NPM/B23 displayed strong nucleoplasmic staining and in the 
metastatic cell line an additional cytoplasmic localization was also observed 
(Figure 5B, Karhemo et al., unpublished results). As seen from Figure 5A, 
only a minor fraction of total cellular NPM was observed at the cell surface 
and is most likely below the detection limit of immunofluorescence. 
5.1.4 The overexpression of cd109 and ITGA6 marks cells derived 
from melanoma metastasis (I) 
 
The 3-dimensional (3D) architecture provided by the ECM at both primary 
and secondary sites, have a profound influence on the functional properties 
of tumor cells (Joyce and Pollard, 2009; Sleeman et al., 2012). Importantly, 
the in vitro observed expression differences of CD109, PTGFRN, PROCR, 
and ITGA6  (table 3) were also detectable in vivo in xenograft tumor samples 
derived from the metastatic and non-metastatic MDA-MB-435 cells (Figure 4 
in publication I).  
To investigate if the differential expression of CD109 and ITGA6 could 
differentiate metastatic cells from non-metastatic ones in other cell models, 
their expression was studied in six melanoma cell lines (WM164, WM165, 
WM793, WM852, G361, and Bowes) and in four invasive (MDA-MB-231, 
BT549, HS578T, SUM159) and four non-invasive (MCF-7, ZR75-1, BT474, 
and T47D) breast cancer cell lines (Neve et al., 2006). CD109 is a GPI-linked 
cell surface protein, which negatively modulates TGFB1 signaling in 
keratinocytes (Finnson et al., 2006; Hagiwara et al., 2010). Expression of its 
transcript has previously been linked to melanoma in a transgenic melanoma 
mouse model (Ohshima et al., 2010) and it is expressed in BLBC (Hasegawa 
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et al., 2008). Shedding of CD109 by mesotrypsin has been shown to promote 
the malignant growth of breast cancer cells (Hockla et al., 2010) but its role 
in metastasis is unknown.  
ITGA6 dimerizes with ITGB4 and the complex functions primarily as an 
adhesion receptor in normal epithelia, often as a component of adhesive 
structures termed hemidesmosomes. The A6B4 complex has been shown to 
play a role in migration, invasion and survival of carcinoma cells, most likely 
by alterations in the localization of A6B4 that influence its signaling capacity 
(Lipscomb and Mercurio, 2005).  
In line with the original proteomic study, CD109 was highly expressed on 
the surface of the cell lines derived from metastatic melanoma (WM164, 
WM165, and WM852) and on the surface of WM793 cells derived from an 
invasive advanced vertical growth phase of melanoma. Cells derived from 
non-metastatic primary melanomas (G361 and Bowes) expressed negligible 
amounts of the protein. ITGA6 was expressed in WM852 and WM793 cells 
while the rest of the cell lines showed very low or undetectable levels of 
ITGA6 (Figure 5 in publication I, control staining in Supplemental Figure 
S2A in publication I). In accordance with its expression in the melanoma cell 
lines, three out of four invasive breast cancer cell lines (BT549, HS578T, and 
SUM159) expressed high levels of CD109 while none of the non-invasive 
breast cancer cell lines expressed detectable amounts of CD109 
(Supplemental Figure S1 in publication I). 
To typify the fibrin-rich tumor–stroma interface of melanomas in vivo, 
the expression of CD109 and ITGA6 was further analyzed in three-
dimensional (3D) matrix composed of cross-linked fibrin (Wojtukiewicz et 
al., 1990). Importantly, when the cells were implanted inside a 3D matrix, 
both ITGA6 and CD109 were highly expressed in the cells derived from 
melanoma metastasis (Figure 6 in publication I, control staining in 
Supplemental Figure S2D in publication I). WM793 cells from advanced 
vertical growth phase primary melanoma also expressed detectable levels of 
CD109 in the 3D culture conditions while ITGA6 was essentially undetectable 
in all the cells derived from primary melanomas (Figure 6 in publication I).  
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Importantly, these results demonstrate the validity of the used cell line 
model and the proteomics approach. The results were validated in vivo and 
in models other than originally used. Therefore, the functional role of C109 
and other identified proteins in metastatic colonization and dormancy should 
be studied in the future. 
5.1.5 Interactome analysis indicates a role for a tetraspanin protein 
complex in metastasis (I) 
 
The role of only about one-third of the significantly differentially expressed 
proteins identified in the gel free LC-MS/MS analysis (23 proteins) is well 
documented in cancer progression and metastasis. To put our novel 
metastasis-associated proteins into biological context we analyzed how the 
proteins identified in the LC-MS/MS analysis (Table 3 and Table 1 in I) 
interacted with each other, and which signaling pathways they were involved 
in using the computational platform Moksiskaan (Laakso and Hautaniemi, 
2010). A two-fold expression difference was used as a threshold for up or 
down regulated proteins. Proteins that showed less than 2-fold expression 
differences were defined as stable (Table 1 in I and Table 4). To simplify the 
pathways and interactomes the HLA-molecules were excluded from the 
analyses resulting in 14 differentially expressed proteins and seven stably 
expressed proteins. Differential expression of HLA-molecules in this cell 
model has been validated in other studies (Leth-Larsen et al., 2009; 
Rasmussen and Ditzel, 2009).  
The known relationships between the candidate proteins were analyzed in 
the Moksiskaan software based on the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways (Figure 2 in publication I) (Kanehisa et al., 
2010). The KEGG pathways supporting these relationships included 
metastasis-associated pathways, such as gap junctions, focal adhesions, and 
insulin signaling pathway (Supplemental information S2, metastasis 
associated proteins p. 5 in  study I).  
The insulin signaling pathway is represented in the analyses via two 
proteins upregulated at the surface of the metastatic cells; fatty acid synthase 
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(FASN) and receptor-type tyrosine-protein phosphatase F (PTPRF, LAR). 
Excess cellular lipid level has previously been associated with cancer 
aggressiveness (Tsubura et al., 2009). Hedegaard et al. demonstrated higher 
unsaturated fatty acid levels in the metastatic MDA-MB-435 cell clone 
relative to the non-metastatic one (Hedegaard et al., 2010). A comparative 
gene expression analysis revealed significantly higher expression of fatty acid 
desaturase 1, which catalyzes the change of saturated fatty acids to 
unsaturated ones, in the metastatic MDA-MB-435 cells compared to the non-
metastatic ones (Montel et al., 2006). This evidence indicates a role of fatty 
acids in the regulation of the metastatic potential of this cell pair. 
PTPRF is a protein tyrosine phosphatase (PTP) that has been reported to 
regulate insulin receptor phosphorylation and signaling (Goldstein et al., 
1998). The extracellular region of PTPRF contains a cell adhesion molecule-
like receptor region and it localizes at focal adhesions (Brady-Kalnay and 
Tonks, 1995), which are important for cell-extracellular matrix interactions 
and adhesion-mediated signal transduction (Wozniak et al., 2004). PTPs can 
either promote or suppress tumor progression and metastasis via either 
enhancing or suppressing cell surface receptor tyrosine kinase signaling 
(Sastry and Elferink, 2011). Upregulation of different forms of PTPs have 
been identified on the surface of the metastatic cells in other studies (Conn et 
al., 2008; Roesli et al., 2009). Interestingly, PTPRF has been shown to 
regulate adhesion between Drosophila male germ line stem cells and the 
niche by promoting E-cadherin-based adhesion (Srinivasan et al., 2012). It’s 
possible role in promoting metastasis via adhesive contacts at the secondary 
site or pre-metastatic niche warrants further studies.  
When analyzing the protein interactions in the candidate pathway we 
observed that three of the identified proteins, ITGA6, prostaglandin receptor 
negative regulator (PTGFRN) and immunoglobulin superfamily member 8 
(IGSF8) interacted with two proteins (CD81 and TSPAN4) in the Moksiskaan 
pathway (Supplemental information S2, metastasis associated proteins p. 16 
in publication I). Interestingly, CD81 and TSPAN4 are members of the 
tetraspanin family, a class of 33 proteins, which all have four transmembrane 
domains with short intracytosolic N- and C-terminal regions, and two 
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extracellular loops. Tetraspanins form specialized membrane microdomains 
on the cell surface, which control cell proliferation and migration through 
various adhesion and growth factor receptors. Tetraspanins interact with 
many different molecules, like integrins, and the composition of the complex, 
known as the tetraspanin web, is altered by various biological stimuli. 
Therefore, the different combinations of tetraspanins and associated proteins 
are biologically more important than individual components present at the 
cell surface. Recent extensive research has shown that expression of various 
tetraspanins and their associated partners is deregulated in human 
malignancies (Lazo, 2007). In regards to the PTGFRN and IGSF8, which 
were upregulated at the surface of the metastatic cells, it would be valuable to 
analyze the composition of the tetraspanin complex instead of the single 
proteins to better understand their role in the regulation of metastatic 
process.  
5.2 Nucleophosmin (NPM/B23) has multiple divergent 
roles in breast cancer (II, III) 
5.2.1 Discovery and characterization of novel NPM splice variants 
B23.3 and B23.4 (III) 
 
As shown in Figure 5B we discovered that the metastatic as well as the non-
metastatic cells both displayed strong nucleoplasmic NPM staining. In 
accordance, no overall expression difference of NPM was detected (Figure 
5A). However, the metastatic cells lacked NPM on their surface and on the 
other hand contained cytoplasmic NPM (Figure 4A and B, respectively). 
Taken together these results indicated that a change in NPM localization 
might play a role in metastasis (Karhemo et al, unpublished data). NPM 
mutations are the most frequent genetic abnormalities found in acute 
myeloid leukemias and cause a cytoplasmic delocalization of the mutant 
NPM protein (Falini et al., 2005). To investigate the reason for the 
differential localization of NPM in the metastatic cells we cloned the gene 
from both metastatic and non-metastatic cells and analyzed its sequence. 
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Although no mutations in the sequences were found the sequence analysis 
revealed a possible explanation for the localization differences; the presence 
of two novel NPM splice variants in these cells. The domain structure and 
sequence alignment of the novel variants are shown in Figure 1 in publication 
III. One of the variants, hereafter referred to as B23.3 has recently been 
described in the human EST database (GenBank accession number: 
NM_199185). The other variant, hereafter referred to as B23.4, has not been 
described in the human EST database.  
Characterization of the cellular localization and dimerization of the novel 
NPM splice variants, B23.3 and B23.4 in U2OS cells, revealed that the B23.4 
could be responsible for the cytoplasmic NPM observed in the metastatic 
cells from which it was originally identified  (Figure 4G and I in publication 
III). According to the immunoprecipitation analysis, B23.4 did not 
oligomerize with the endogenous NPM (Figure 2 in III). This is not 
surprising taken into account that B23.4 lacked part of the oligomerization 
site at the N-terminus of the NPM-protein (Figure 1 in III).  
B23.3 localized to the nucleoli and nucleoplasm (Figure 4D and F and 5D 
and F in publication III) and oligomerized with the endogenous NPM (Figure 
2 in publication III). Interestingly, different NPM forms were detected in 
cells overexpressing the full-length NPM (B23.1) or B23.3 indicating that 
they formed distinct complexes in the cell (Figure 2 in publication III). The 
nature of these complexes is currently unknown but the observation is 
important because the cellular function of NPM is heavily affected by its 
modifications together with homo- and hetero-oligomers. Overexpression of 
neither of the two novel splice variants affected proliferation of U2OS cells 
(Figure 3A in publication III) but both affected their phenotype and post-
confluent growth (Figure 3B in III). The observed phenotypic differences 
were also reflected in the actin filaments visualized by phalloidin staining 
(Figure 3C in III). 
Our results obtained from the initial characterization of the novel NPM 
splice variants indicated that these variants are functional and therefore most 
likely expressed also at protein level in the cells. NPM has been shown to play 
diverse cellular roles depending on the cell type. Therefore, to better 
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understand the biological significance of these novel splice variants it will be 
important to study them in other cell types in addition to the U2OS cells.  
Our discovery of novel NPM splice variants in addition to the previously 
characterized B23.2, which lacks 35 amino acids at the C-terminus (Wang et 
al., 1993) adds another layer of complexity to NPM’s biology and highlights 
the need to interpret the results obtained from NPM studies in respect to not 
just the localization or oligomerization but in regards to the isoforms. All the 
isoforms seem to either lack highly specific functional domains (B23.2 and 
B23.3) or only contain certain domains (B23.4) indicating that the various 
and often seemingly antagonistic functions of NPM might regulated by its 
functional domains. To shed more light on the biological significance of the 
novel NPM splice variants their expression pattern in normal tissues under 
various developmental stages and in cancer tissues of multiple origin should 
be analyzed. 
5.2.2 Analysis of the prognostic significance of different NPM forms 
in breast cancer (II, III) 
 
One approach to validate the relevance of observations made in experimental 
models is to analyze patient-derived material by using TMAs. Furthermore, 
such studies may identify candidate biomarkers for functional investigation. 
Despite the vast literature on NPM, to our knowledge, no analysis of the 
relevance of its expression or localization in regard to breast cancer 
prognosis was performed. Zhu et al. (2006) analyzed the nuclear expression 
of NPM in 44 breast cancer patient revealing that in 95% of cases (42/44) 
>50% of tumor cell nuclei were positive for NPM. However, the differences in 
intensity or prognostic value were not analyzed (Zhu et al., 2006).  
To reveal the significance of NPM localization and/or expression level in 
breast cancer we investigated its expression level and localization in a large 
array of patient material (n =1160), the FinProg breast cancer database 
(Joensuu et al., 2003). To reveal the possible role of B23.3 , which lacked an 
important Thr199 phosphorylation site, in breast cancer we analyzed 
expression of the Thr199 phosphorylation (pThr199) in the same FinProg 
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database. To obtain a more comprehensive view a second breast cancer 
database, the FinHer cohort (Joensuu et al., 2009; Joensuu et al., 2006), was 
also analyzed  for pThr199 (n=857). Both databases contain detailed clinical 
information and follow-up data for the patients enabling survival analysis 
and correlation with other known prognostic markers for NPM and its 
Thr199 phosphorylation.  We also analyzed 14 histologically normal breast 
tissue samples originating from breast reduction surgery for their NPM 
expression for the comparison of NPM expression in breast cancer. Results 
from these studies are summarized in table 4. and discussed below. 
 
Table 4. Different NPM forms analyzed in this study 
NPM 
form 
Observed 
in 
Prognostic 
factor 
Independent 
prognostic 
factor 
(subtype) 
More 
frequent 
in 
Study 
Cell 
surface 
NM-435 ND ND ND 
 
Cyto-
plasmic 
M-435, 
BCPM 
No ND ND I 
B23.3 435 ND ND ND III 
B23.4 M-435 ND ND ND III 
High 
NPM 
levels 
BCPM 
Associate 
with with FP 
Yes 
(luminal A) 
No II 
Granular 
NPM 
BCPM 
Associate 
with PP 
Yes 
(whole 
material, 
adjuvant 
chemotherapy) 
Basal-like, 
unclassifie
d 
II 
pThr199 BCPM 
Associate 
with PP 
No Basal-like III 
NM-435  = non-metastatic MDA-MB-435 subclone, 
M-435 = metastatic MDA-MB-435 subclone, 
BCPM = breast cancer patient material, 
ND = not determined,  FP = favourable protgnosis, PP = poor 
prognosis 
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5.2.3 NPM expression levels affected its localization  (II) 
 
In our analysis, NPM was expressed at high levels in the luminal epithelial 
cells of all histologically normal breast tissue samples (Figure 1A, B and E in 
publication II). Similar intense, nuclear staining of the epithelial cells of the 
milk ducts has been detected in another study (Rower et al., 2011) indicating 
that under normal conditions, the luminal epithelial cells have high levels of 
total NPM. Interestingly, in our histologically normal breast tissue samples 
the younger women displayed uniform nuclear NPM localization (Figure 1A 
in publication II) while the older ones showed only nucleolar localization 
(Figure 1B in publication II). By using qPCR analysis and ectopic 
overexpression of NPM we showed that NPM expression level affected its 
localization (nucleolar or nucleoplasmic, Figure 1G-I in publication II). We 
confirmed the previously published results (Cicatiello et al., 2004; Skaar et 
al., 1998) that NPM expression is up-regulated by estrogen treatment  in 
breast cancer cell lines (Figure 2A and B in publication) and showed that this 
upregulation leads to increase in the nucleoplasmic NPM (Figure 2C-F in 
publication II). Since estrogen levels commonly decrease at menopause in 
older women our results suggest that NPM expression level affected its 
localization in the.  In accordance with our findings, UV treatment (stress) 
induces up-regulation of NPM expression and changes its localization from 
nucleolar to even nuclear distribution (Wu and Yung, 2002).  If and how the 
effects of the stress-induced nucleoplasmic localization of NPM (Chan et al., 
1985; Yang et al., 2002; Kurki et al., 2004) differ from the nucleoplasmic 
localization in the breast epithelial cells is unknown. 
In the breast cancer samples analyzed, NPM was detected at various 
localizations: solely in the nucleolus (14%, Figure 3A, F in II), evenly 
distributed throughout the nucleus (55%, Figure 3 B, G in II), and only in the 
nucleoplasm (31%, Figure 3 C, H in II). We also observed a rare, cytoplasmic 
staining for NPM (7%, Figure 3 D, I in II). However, no correlation between 
the patient prognosis and these NPM localizations was observed in the study. 
In contrast to histologically normal breast tissue, no correlation between the 
NPM localization and age was detected in the tumor specimens (P = 0.67) 
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and no mutations explaining the differences were found (Supplemental table 
S1 in  publication II).  
5.2.4 Tumor suppressive role for NPM in breast cancer (II) 
 
Importantly, NPM expression was reduced in breast cancer as compared to 
histologically normal breast tissue and  patients with reduced levels of NPM 
showed increased risk of developing a metastatic disease as judged by distant 
disease free survival (DDFS, time from diagnosis to the occurrence of either 
metastases outside the region in which the tumor arose or death from breast 
cancer) (Figure 4A and supplemental Table S3 in publication II). In a 
subgroup analysis NPM levels showed significant prognostic value in ER-
positive, p53-/low and HER-negative breast cancers. More importantly, NPM 
expression levels served as an independent prognostic factor for metastatic 
disease and/or breast cancer caused death in the luminal A subgroup of 
breast cancer (Figure 4B in II and Table 2 in II). The luminal A tumors in our 
analysis were classified as ER-and/or PR-positive and HER-negative, which 
explains the observed prognostic value in these subgroups. The prognostic 
value in p53-/low-groups, which most likely have a wild type p53, can be 
explained by the knowledge that only about 12-15% of luminal A tumors 
harbor p53 mutations (Carey et al., 2006; Cancer Genome Atlas Network, 
2012). Luminal B tumors differ from the luminal A ones in respect to HER2 
expression. NPM expression showed no prognostic value in this subtype or in 
HER2-positive tumors indicting that HER2 overexpression overrode the 
prognostic significance of NPM.  
Our results revealed that overexpression of NPM in the invasive MDA-
MB-231 cells abrogated their growth in soft agar (Figure 5 in II) suggesting a 
tumor suppressive role for NPM in breast cancer. Contradictory to our 
results, high NPM expression has been associated with poor prognosis or 
recurrence in other tumor types (Kikuta et al., 2009; Tsui et al., 2008; Liu et 
al., 2012; Coutinho-Camillo et al., 2010). However, in the cases where NPM 
expression in the corresponding normal tissue was analyzed, it was markedly 
lower than in the cancer tissue highlighting the context dependent role for 
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NPM in neoplasia. Too much or too little NPM could disrupt the cellular 
homeostasis leading to deregulated growth. 
5.2.5 Granular staining pattern as indicator of metastatic disease (II) 
 
Interestingly, 14% of the breast cancer samples showed a very distinct, 
granular staining for NPM (Figure 3E and J in publication II). A similar 
staining patter has previously been identified in colorectal carcinoma 
(Nozawa et al., 1996) but its significance has not been analyzed. In this thesis 
work the presence of the granular staining pattern associated with agressiwe 
breast cancer characters and basal subtype (Supplemental Table S2 in 
publication II). Moreover, patients that showed granular NPM were more 
prone to develop metastatic disease or die of breast cancer than patients with 
non-granular NPM (Figure 4C in publication II) in several subgroups 
(Supplemental Table S4 in II) including luminal A (Figure 4D in II). More 
importantly, in a Cox proportional hazards model the granular staining 
pattern proved as an independent prognostic factor of distant, metastatic 
disease or breast cancer death in the whole series (Table 3 in II, P = 0.04). 
Patients displaying granular staining pattern of NPM appeared less likely to 
benefit from chemotherapy (Figure 4, E and F in II and Table 4 in 
publication II). The cause of the granular NPM is currently unknown but the 
mechanisms behind it would be interesting to resolve since they might shed 
light on the contradiction between the oncogenic and tumor suppressive 
functions of NPM. 
5.2.6 Thr199 phosphorylation of NPM as an indicator of recurrence 
(III) 
 
Interestingly, Thr199 phosphorylation (pThr199) of NPM associated with 
development of distant, metastatic disease and death from breast cancer 
(DDFS, P=0,016, Figure 7A in III) in the NPM positive (moderate or high 
expression) breast cancers in the FinProg dataset. This result suggest that 
Thr199 phosphorylation of NPM overrides the tumor suppressive effect 
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observed for the high total NPM levels and that NPMpThr199 represents an 
oncogenic form of the NPM protein. In support of this, pThr199 significantly 
associated with poor overall survival (P=0,013, Figure 7B in publication II) 
and distant disease recurrence, in other words metastatic disease (P=0,008, 
Figure 7C in publication II) in the FinHer material that contains patients 
with more aggressive disease. In this respect, the NPMpThr199 resembled 
the granular staining pattern. Both NPM forms were also more frequently 
observed in basal type breast cancers. These two forms of NPM showed 
inverse correlation in the FinProg breast cancer patients (Table 1 in III) 
indicating a connection between them. The nature of this connection, 
however, is totally unclear. Since nothing is known about the molecular basis 
of granular NPM, it is impossible to speculate the underlining mechanisms 
behind the similar behavior and connection between the granular NPM and 
Thr199 phosphorylation of NPM. 
5.2.7 Thr199 phosphorylation of NPM associated with aggressive 
breast cancers and CIP2A expression (III) 
 
Cancerous inhibitor of protein phosphatase 2 (CIP2A) has recently been 
identified as an oncogene (Junttila et al., 2007). Intriguingly, we 
demonstrated that NPMp Thr199 associated with CIP2A expression in both 
breast cancer cohorts analyzed (Table 1 in III and Figure 6A in publication 
III). Moreover, a significant reduction in pThr199 levels was observed at day 
4 and 5 after siRNA mediated silencing of CIP2A (Figure 6B in III) 
confirming the association observed in the patient analysis. CIP2A also 
seemed to associate with total NPM levels in the patient material. In 
accordance, a slight increase in total NPM levels was evident at day 3 after 
CIP2A silencing, but this was not detected at later time points (Figure 6B in 
III).  
Thr199 of NPM is dephosphorylated by a protease distinct from PP2A, 
PP1beta (Lin et al., 2010). In addition, CIP2A silencing increased the 
pThr199 at day 3 after which a clear reduction was observed (Figure 6B in 
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III). This together with the different cellular localizations of CIP2A and NPM 
indicate that Thr199 is not a direct target of PP2A.  
The expression of CIP2A (Côme et al., 2009; Niemela et al., 2012) and the 
NPMpThr199 both associated with aggressive characteristics of breast cancer 
(p53 expression indicative of mutant p53 and basal-type, Table 1 in 
publication III). These two proteins  participate in the regulation of the same 
pathways like c-myc (Niemela et al., 2012; Bockelman et al., 2012; Guo et al., 
2000; Neiman et al., 2001; Kim et al., 2000; Zeller et al., 2001; Li and Hann, 
2013; Li et al., 2008) and E2F1 (Lin et al., 2010; Lin et al., 2006; Takemura 
et al., 2002; Takemura et al., 1999; Liu et al., 2009; Laine et al., 2013). In 
addition, in our analysis, pThr199 significantly associated with EGFR 
expression (Table 1 in publication III) and the CIP2A has shown to be 
regulated by the EGFR-MEK1/2 ETS signaling pathway (Khanna et al., 2011). 
The detailed molecular mechanism behind the connection between 
NPMpThr199 and CIP2A warrants further experimental analyses to resolve if 
CIP2A is responsible for the association between NPMpThr199 and 
development of metastatic disease in breast cancer.  
5.2.8 NPM modifications and metastasis? 
 
In this thesis, by using two distinct large breast cancer TMA datasets, we 
have revealed that, in respect of development of metastatic disease and 
breast cancer death, different NMP forms have contradictory roles in breast 
cancer (summarized in Table 4).  To our knowledge, this is the first analysis 
comparing the significance of different NPM forms (total levels, granular 
NPM and Thr199 phosphorylation) in any cancer material. Interestingly, 
high total NPM levels associated with favourable prognosis and reduced risk 
of metastatic disease and/or death from breast cancer only in luminal A 
breast tumors while its expression did not significantly vary among the 
different subtypes (Supplemental Table S2 in publication II). On the 
contrary, granular staining and Thr199 phosphorylation were more frequent 
in basal-like breast cancers and served as indicators of metastatic disease in 
whole patient material. As described in the Review of the literature, NPM 
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participates in the regulation of p53 and RB-pathways. Interestingly, vast 
majority of luminal A tumors harbor wt p53 while this protein is mutated or 
inactivated in most BLBCs (Carey et al., 2006; Cancer Genome Atlas 
Network, 2012; Dumay et al., 2013). In addition, in most BLBCs tumor 
suppressor RB is affected (Gauthier et al., 2007; Herschkowitz et al., 2008; 
Subhawong et al., 2009). If these molecular differences affect the role of 
NPM and its different forms in breast cancer should be analyzed in the 
future.  
Previously, in a comparative proteomic analysis the phosphorylation of 
NPM serine 125 has been shown to be more abundant in cancer samples than 
in controls (Rower et al., 2011). In addition, a 2D gel analysis identified an 
unknown NPM modification to be more abundant in metastatic breast 
tumors than in their non-metastatic counterparts (Vydra et al., 2008). 
Moreover, this thesis works revealed a novel NPM splice variant from 
metastatic cells and a connection between NPMpThr199 and a known 
oncogene and modulator of post-translational modifications, CIP2A. Taken 
together these findings propose that postranslational modifications and 
domain structure changes affecting these modifications in NPM might be  
general mechanisms to control NPM’s function in breast cancer. To make the 
picture more complicated, NPM’s oncogenic potential is also modified by 
plakoglobin (PG, γ-catenin), a homolog of β-catenin with dual adhesive and 
signaling functions (Lam et al., 2012) and HLJ1, a tumor suppressor and a 
member of the heat shock protein 40 chaperone family (Chang et al., 2010). 
In addition, NPM has been shown to suppress of CXCR4-mediated G protein 
activation and chemotaxis via directly interacting with CXCR4. CXCR4 is the 
primary receptor for CXCL12, which is secreted by metastatic sites and 
promotes homing of CXCR4 expressing tumor cells to these sites (Zhang et 
al., 2007). 
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6 CONCLUSIONS AND FUTURE 
PROSPECTS 
One aim of this thesis work was to identify novel cell surface proteins 
associated with metastasis colonization and dormancy. Importantly, this 
study resulted in the discovery of a several novel metastasis associated 
proteins and opened up interesting connections for further studies. Out of 
the identified proteins, CD109 proved as a promising novel candidate for 
future analyses. In addition to the conventional cell surface proteins the 
proteomic comparison revealed novel cell surface proteins. Intracellular 
proteins are increasingly observed in extracellular space highlighting the 
need to reconsider the classical protein localizations. Importantly, in respect 
to drug target discovery a protein that is a therapeutic target in one cellular 
location may have anti-target activity elsewhere. 
The present study demonstrated for the first time analysis of different 
NPM forms in the same patient material. Strikingly, different NPM forms 
(total levels, granular staining and pThr199) behaved in opposite ways 
indicating the need to critically evaluate results concerning NPM’s function 
and prognostic relevance. NPM cannot be considered as a single entity but in 
the future more effort should be put to analyses to study if similar 
relationships are present in other tumor types. In respect to NPM as a drug 
target one should carefully consider all the possible effects the drug might 
have on NPM’s function.  
The pThr199 associated with CIP2A expression. The positive prognostic 
role of NPM was evident in luminal A tumors, which rarely harbor p53 
mutations. The poor prognostic function was evident in basal type breast 
cancer commonly harboring a mutant p53. The connection of NPM to p53 
and CIP2A should be analyzed at functional level.  
Finally, this study revealed the presence of two novels splice variants of 
NPM, B23.3 and B23.4, in cancer cells. In the future their molecular 
function, expression pattern at the tissue level and possible role in regulation 
of metastatic dissemination of cancer should be studied.  
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